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ABSTR4.CT 
The first objective of the present study was to determine whether the Theory of 
Planned Behaviour (TPB) could predict 'Willingness to Participate (WTP) in a future 
Phase III HIV vaccine trial among high risk adolescents in the Westem Cape. The 
second objective was to detennine whether the additional predictor variables of Self-
perceived risk of HIV infection, K..'1owledge of HIV vaccines and HIV vaccine trials, 
Attitudes toward HIV I AIDS and Health-promoting behaviours could further explain 
WTP in a future Phase III HIV vaccine trial among adolescents. A convenience 
sample of 224 adolescents attending secondary schools located in an African 
township on the Cape Flats was recruited for the present study. Hierarchical logistic 
regression analyses indicated that the TPB significantly improved the prediction of 
WTP in an HIV vaccine trial. Prediction success was 79.9%. Of all the predictor 
variables, only Subjective nmms significantly predicted WTP in an HIV vaccine trial 
(OR = 1.19,95% C.L = 1.06-1.34). A second stepwise logistic regression analysis 
showed that Subjective nonns (OR = 1.19, 95% c.I. = l.07-1.34) and Attitude 
towards pm1icipation in an HIV vaccine trial (OR = 1.32,95% C.L = 1.00-1.74) were 
significant predictors of WTP in an HIV vaccine trial. Prediction success was 80.4%. 
These findings provide support for the Theory of Reasoned Action (TRA.) and 
suggest that psychosocial factors may playa role in WTP in a future Phase III HIV 
vaccine trial among adolescents. HIV vaccine trial preparedness programs targeting 
adolescents should aim to influence group nonns positively and promote positive 
attitudes toward participation in a future Phase III HIV vaccine triaL 
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IV 
OPSOMMING 
Die eerste oogmerk van die huidige studie was om te bepaal of die teorie van 
beplande gedrag (TBG) die bereidwilligheid tot deelname (BTD) aan 'n toekomstige 
fase III-MIV-entstofproefneming onder hoe risiko adolessente in die Wes-Kaap kan 
voorspel. Die tweede oogmerk was om te bepaal of die bykomende 
voorspellingveranderlikes, naamlik selfwaargenome risiko vir MIV -besmetting, 
kennis van MIV -entstowwe en MIV -entstofproefnemings, houdings j eens MIV Ivigs 
en gesondheidsbevorderende gedrag BTD in 'n toekomstige fase Ill-MIV-
entstofproefneming kan verduidelik. 'n Geriefsmonster van 224 adolessente wat 
sekondere skole gelee in 'n dorpsgebied in Kaapstad, bywoon, is vir die huidige 
studie gewerf. Hierargiese logistiese regressie-analises toon da! die TBG die 
voorspelling van BTD aan 'n MIV -entstofproefneming aanmerklik verbeter het. 
Voorspellingsukses was 79.9%. Van al die voorspellingveranderlikes het slegs 
subjektiewe nom1e BTD aan 'n MIV -entstofproefneming beduidend voorspel (RK = 
1.19, 95% VI = 1.06-1.34). 'n Tweede stapsgewyse logistiese regressie-analise toon 
dat subjektiewe norme (RK = 1.19, 95% VI = 1.07-1.34) en houding jeens deelname 
aan 'n MIV-entstofproefneming (RK = 1.32,95% VI = 1.00-1.74) beduidende 
voorspellers van BTD aan 'n MIV -entstofproefneming was. Voorspellingsukses was 
80.4%. Hierdie bevindinge verleen steun aan die teorie van beredeneerde aksie (TBA) 
en doen aan die hand dat psigososiale faktore moontlik in die toekoms 'n rol in BTD 
aan 'n fase Ill-MIV-entstofproefneming onder adolessente kan speel. Programme wat 
op adolessente se gereedheid vir entstofproefnemings afgestem is, behoort te poog om 
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groepnorrne positief te beinvloed en positiewe houdings jeens deelname aan 'n 
toekomstige fase III -MIV -entstofproefneming te bevorder. 
v 
Stellenbosch University  http://scholar.sun.ac.za
VI 
ACKNO\VLEDGEMENTS 
I would like to thank the outstanding Professor Ashraf Kagee for his enduring 
supervision and support this year. I would like to thank him for aiways having my 
best interests at mind, for guiding me and for making research funds available to me. 
Above all else, I would like to thank him for making this year the most beneficial 
year of my life yet. Special thanks to my wonderful parents for all they have done to 
get me this far. For their love, support, encouragement and undying faith in my ability 
to complete this degree. Not to mention, their financial support. Without them, I 
couldn't have accomplished this. Thanks are due to the rest of my wonderful family 
and friends for standing by me through this very lengthy and solitary process. Thanks 
to Dylan, your continuing encouragement this year kept me going at the worst of 
times! I would like to thank the members of the SAA VI Socio-behavioural working 
group at Stellenbosch University for all their assistance. I am extremely grateful to 
them for all their guidance and input. I am also grateful to the school principals and 
HIV counselor for accommodating me and for all the assistance in organising the data 
collection. Thank-you to Renier for his assistance in the data collection. I couldn't 
have done it \vithout him there! Thank-you to Professor Nel and Dr Kidd for their 
statistical advice. Thank-you to Marieanna Ie Roux for her help and advice in the 
support groups! Last but not least, the biggest thanks and acknowledgement goes to 
Jaco for being the stability in my life. For making me want to pursue my dreams and 
for picking me up when I fall. No amount of words could ever express my gratitude 
to you! 
G Giocos (November 2006) 
Stellenbosch University  http://scholar.sun.ac.za
Vll 
DEDICATION 
I dedicate this thesis to the participants in my study, for so willingly and tolerantly 
filling in the questionnaires. May this thesis contribute to the eventual development of 
a safe and effective preventative HIV vaccine. 
Stellenbosch University  http://scholar.sun.ac.za
Declaration 
Abstract 
Opsomming 
Aclmowledgements 
Dedication 
List of Tables 
List of Figures 
Chapter 1: Introduction 
TABLE OF CONTENTS 
1.1 The global AIDS epidemic 
1.2 Sexual behaviour among adolescents in South Africa 
vln 
11 
111 
IV 
VI 
VII 
XIV 
XV 
1.3 The HIV preventative vaccine 2 
lA Predicting Willingness to Participate (\ViP) in an HIV vaccine trial 3 
1A.1 Perceived risk of HIV infection 3 
1A.2 Knowledge of HIV vaccines and HIV vaccine trial processes 3 
1A.3 Attitudes toward HIV/AIDS 4 
1AA Health-promoting behaviours 4 
lA.5 Theoretical framework 5 
1.5 Definition of adolescence 
1.6 Objectives of the present study 
Chapter 2: Literature review and theoretical framework 
2.1 Perceived risk of HIV infection 
2.2 Knowledge of HIV vaccines and HIV vaccine trials 
6 
6 
7 
7 
8 
Stellenbosch University  http://scholar.sun.ac.za
IX 
2.2.1 Infonned consent 9 
2.2.2 Knowledge of HI V vaccines and VviP in an HIV vaccine trial 10 
2.3 Attitudes toward HIV / AIDS 
2.4 Health-promoting behaviours 
2.5 Demographic characteristics 
2.5.1 Age 
2.5.2 Gender 
2.5.3 Education 
2.5.4 Race 
2.6 Theoretical framework 
2.6.1 The Theory of Planned Behaviour (TPB) 
2.6.2 The TPB and WTP in an HIV vaccine trial 
2.7 Application of the TPB in the present study 
Chapter 3: Research Methodology 
3.1 Research design 
3.2 Patiicipants 
3.3 Procedure 
3.4 Measuring instruments 
3.4.1 Demographic variables 
3.4.2 Perceived risk of HIV infection 
3.4.3 Willingness to participate (WTP) in an HIV vaccine trial 
3.4.4 Knowledge of HI V vaccines and HIV vaccine trials 
3.4.5 Attitude towards HIV/AIDS 
13 
16 
18 
18 
18 
18 
19 
19 
21 
23 
23 
27 
27 
27 
27 
27 
27 
27 
28 
28 
29 
Stellenbosch University  http://scholar.sun.ac.za
x 
3.4.6 Health-promoting behaviours 29 
3.4.7 Attitude towards participation in an HIV vaccine tlial 32 
3.4.8 Subjective norms 
3.4.9 Perceived behavioural control 33 
3.5 Data analysis 33 
3.5.1 Predicting Willingness to participate in an HIV vaccine trial 34 
Chapter 4: Results 36 
4.1 Demographic charactelistics of the sample 36 
4.2 Data screening and tests of parametric assumptions 37 
4.3 Internal consistency of measurement instmments used in the present study 39 
4.3.1 Knowledge of HIV vaccines and HIV vaccine trials 39 
4.3.2 The AIDS-related Stigma Scale 40 
4.3.3 The Health-Promoting Lifestyle Profile 40 
4.3.4 Attitude towards participation in an HIV vaccine trial 40 
4.3.5 Subjective norms 40 
4.3.6 Perceived behavioural control 40 
4.4 Analysis of demographic variables 41 
4.4.1 Age 41 
4.4.2 Grade 41 
4.4.3 Gender 41 
4.5 COlTelations between predictor variables and \VTP 42 
4.5.1 Perceived risk of HIV infection 42 
4.5.2 Knowledge of HIV vaccines and HIV vaccine tlials 42 
Stellenbosch University  http://scholar.sun.ac.za
4.5.3 Attitude towards HIV/AIDS 
4.5.4 Health-promoting behaviours 
4.5.5 Subjective norms 
4.5.6 Attitude towards participation in an HIV vaccine tlial 
4.5.7 Perceived behavioural control 
Xl 
42 
42 
43 
43 
43 
4.6 Predicting Willingness to Participate in a future Phase III HIV vaccine 45 
trial 
4.6.1 Regression model 1 
4.6.2 Results of regression model 1 
4.6.3 Regression model 2 
4.6.4 Results of regression model 2 
Chapter 5: Discussion and Conclusion 
5.1 Predicting WTP in a future Phase III HIV vaccine trial 
(regression model 1) 
46 
47 
49 
50 
53 
53 
5.1.1. Subjective norms as a predictor variable of WTP in a future 54 
Phase III HIV vaccine trial 
5.2 Predicting WTP in a future Phase III HIV vaccine trial 
(regression model 2) 
56 
5.3 Attitude towards participation in an HIV vaccine trial as a predictor of 58 
vVTP in a future Phase III HIV vaccine trial 
5.4 Perceived behavioural control as a predictor ofWTP in a future Phase III 58 
HIV vaccine trial 
5.5 Self-perceived risk of HI V infection as a predictor ofWTP in a future 
Stellenbosch University  http://scholar.sun.ac.za
XlI 
Phase III HIV vaccine trial 60 
5.6 Knowledge of HI V vaccines and HIV vaccine trials as a predictor of 61 
WTP in a future Phase III HIV vaccine ttial 
5.7 Attitudes toward HIV/AIDS as a predictor of\VTP in a future Phase III 62 
HIV vaccine trial 
5.8 Health-promoting behaviours as a predictor of WTP in a fhture Phase III 63 
HIV vaccine trial 
5.9 Demographic characteristics 
5.9.1 Age 
5.9.2 Gender 
5.9.3 Education 
5.9.4 Race 
5.10 Implications and social relevance 
5.11 Limitations 
5.12 Directions for future research 
References 
Appendices 
Appendix A 
Appendix B 
Appendix C 
Appendix D 
Appendix E 
Appendix F 
63 
63 
64 
64 
64 
64 
65 
65 
66 
77 
77 
81 
83 
87 
89 
91 
Stellenbosch University  http://scholar.sun.ac.za
Appendix G 
Appendix H 
Xill 
92 
94 
Stellenbosch University  http://scholar.sun.ac.za
XIV 
LIST OF TABLES 
Table 1: Items and Factor Loadings of the Shortened Version of the HeaIth-
31 
Promoting Lifestyle Profile (N = 15) 
Table 2: Demographic Characteristics of the Sample 36 
Table 3: Normality Test for Dependent Variable and Independent Variables 39 
Table 4: Speannan's Intercorrelations Between Demographic Variables and 
Willingness to Patiicipate (WTP) in a future Phase III HIV Vaccine 42 
Trial eN = 202) 
Table 5: Speannan's lntercorrelations Between Predictor Variables and 
Willingness to Participate in an HIV Vaccine Trial (N =194) 
Table 6: Goodness-of-fit Test Statistics and R2 for the Hierarchical Multiple 
Logistic Regression Analysis 
Table 7: Summary of the Hierarchical Multiple Logistic Regression Analysis 
44 
46 
for Variables Predicting 'Willingness to Participate (WTP) in a future 48 
Phase III HIV Vaccine Trial (N = 194) 
Table 8: Goodness-of-fit Test Statistics and R2 for the Forward Stepwise 
50 
Multiple Logistic Regression Analysis 
Table 9: Summary of the Forward Stepwise Multiple Logistic Regression 
Analysis for Variables Predicting Willingness to Pmiicipate (WTP) in 52 
a future Phase III HIV Vaccine Trial (N = 194) 
Stellenbosch University  http://scholar.sun.ac.za
LIST OF FIGURES 
Figure 1: Components of the Theory of Reasoned Action 
Figure 2: Components of the Theory of Planned Behaviour 
Figure 3: Use of the Theory of Planned Behaviour in the present study 
xv 
20 
22 
26 
Stellenbosch University  http://scholar.sun.ac.za
1.1 The global AIDS epidemic 
CHAPTER 1 
INTRODUCTION 
Regardless of the ongoing effOlis to reduce high risk sexual behaviour and encourage the use of 
preventative contraceptives, HIV / AIDS is currently the most infectious disease as well as the most common 
cause of death in Africa (Esparza & Bhamarapravati, 2000). More than 25 million people have died from 
HIVI AIDS related causes since 1981 (UNAIDS/WHO, 2006). By the end of 2005,40.3 million people were 
living with HIV/AIDS worldwide. Moreover, 4.9 million people became newly infected with HIV in 2005 
and a total of 3.1 million people died of HIV / AIDS related causes in 2005 alone. Young people aged 15-24 
account for half of all new HIV infections worldwide, with approximately 6000 young people becoming 
infected with HIV every day (UNAIDS/WHO, 2006). 
1 
The majority of people (96%) infected with HIV live in the developing world, with the greater part in 
sub-Saharan Africa (Global Health Council, 2006). UNAIDS/WHO (2006) report a total of24.5 million 
people living with HIV/ AIDS, 2.7 million newly infected individuals and 2 million deaths in sub-Saharan 
Africa for 2005. In South Africa, an estimated 5.5 million people were living with HIV/AIDS at the end of 
2005 (UNAIDS/\VHO, 2006). The national antenatal survey showed that the HIV prevalence rate was 29.5% 
in 2004 (South African Department of Health, 2005). Moreover, the HIV prevalence rate for individuals 
under the age of 20 was estimated at 16.1 % and 30.8% for individuals aged 20-24. The HIV prevalence rate 
for the Western Cape was estimated at 15.4% (South African Department of Health, 2005). 
1.2 Sexual behaviour among adolescents in South Africa 
It appears that South African adolescents commence sexual activity at an early age: a study conducted 
in a rural area of South Africa found that 76% of girls (with a mean age of 15) and 91 % of boys (with a mean 
age of 16) reported being sexually active (Buga, Amoko, & Ncayiyana, 1996). Other studies have confirmed 
early sexual debut (Kuhn, Steinberg, & Matthews, 1994; Visser, 1995) as well as multiple sexual partners 
among South African adolescents (Richter, 1996, cited in Hartell, 2005). Despite relatively good knowledge 
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levels and awareness of HIVI AIDS among these samples, low self-perceived susceptibility to HIV infection 
partly accounts for the high-risk sexual behaviour among South Aflican adolescents (Galloway, 1999; Kuhn 
eta!',1994). 
Given the position of sexual behaviour among adolescents in South Africa and the alanning HIV 
prevalence rate among this population, HIV I AIDS prevention is a priority for young people, especially as 
adolescence represents a period of discovering and experiencing sexuality and, for some, the use of drugs 
(Redjimi & Lert, 1993). 
1.3 The HIV preventative vaccine 
An effective, safe and affordable HIV preventative vaccine offers the most promising long-term hope 
to control the global epidemic (Esparza & Bhamarapravati, 2000). Moreover, it has been identified as a 
highly desirable goal and is becoming increasingly important (Smit et aI., 2005). Hmvever, aside from the 
fact that trial participants risk exposure to an experimental vaccine that has not been widely tested on human 
subjects (in the case of Phase II and III trials), by participating in an HIV vaccine trial, these individuals are 
required to endure many inconveniences (McCluskey, Alexander, Larkin, Murguia, & Wakefield, 2005). 
Moreover, in order to test vaccine efficacy, a minimum of two thousand HIV-negative participants who are at 
high risk of HIV infection are required to pmiicipate in a Phase III HIV vaccine trial. Enrolment in a Phase 
III HIV vaccine trial entails regular assessment over a number of years (Grinstead, 1995). Subsequently, 
these requirements raise the question of whether individuals at high risk of HIV infection will be interested in 
volunteering for such trials. Moreover, as stated by Mugusi et a1. (2002) there is an additional concern of 
whether volunteers in Phase III HIV vaccine trials can be retained over the long-periods of time required to 
test vaccine efficacy. The recruitment and retention of Phase III HIV vaccine trial participants is therefore 
very important to provide evidence for efficacy of the candidate vaccine (O'Connell et al., 2002). 
In addition to these considerations. there are also ethical considerations. Volunteers in a Phase III 
HIV vaccine trial are required to provide informed consent before enrolment in such a trial (Lindegger & 
Richter, 2000). In the event of high levels of illiteracy, individuals may not fully understand vaccine tlial 
processes and concepts and subsequently be drawn into participating by incentives (Lindegger, Slack, & 
Stellenbosch University  http://scholar.sun.ac.za
3 
Vardas, 2000). It is therefore imperative that research examines knowledge of research procedures and HIV 
vaccines among potential participants before the onset of Phase III HIV vaccine trials. As stated by Esparza 
and Bhamarapravati (2000), to ensure the future availability of HIV vaccines, preclinical research efforts 
need to be improved. 
1A Predicting Willingness to Participate (WTP) in an HIV vaccine trial 
There has been extensive international research conducted on \VTP in HIV vaccine trials (e.g.: 
Celentano et aI., 1995; Golub et aI., 2005; Koblin, Holte, Lenderking, & Heagerty, 2000; MacQueen et a1., 
1999; O'Connell et al., 2002; Strauss et aL, 2001). Additionally, the completion of the first Phase III HIV 
vaccine trials in the United States and Thailand has motivated similar studies in developing countries. 
Nonetheless, there is a lack of valid data focusing on the issues that affect WTP in HIV vaccine trials in the 
South African context as well as other developing countries where the epidemic is paramount (Smit et a1., 
2006). Moreover, a review of the literature revealed that there is an absence of valid data on the appraisal of 
this construct among South African adolescents. Consequently, this indicates an urgent need to gain an 
understanding of WTP in future HIV vaccine trials and to identify the issues that potentially affect WTP in 
future Phase III HIV vaccine trials among individuals who are at high risk of HIV infection. 
lA.1 Perceived risk of HIV infection 
There is evidence that perceived risk of HIV infection is significantly related to \VTP in an HIV 
vaccine trial (e.g.: Jenkins et aL, 2000; Johnson, 2000; Kiwanuka et al., 2004; McGrath et aL, 2001; Newman 
et al., 2006; O'Connell et aI., 2002; Perisse et a1., 2000; Sahay et a1., 2005; Sherr, Bolding, & Elford, 2004; 
Smit et a1., 2006; Starace et al., 2006). There is however a paucity of research focusing on this relationship 
among South African adolescents. The relationship between self-perceived risk of HIV infection and WTP in 
future Phase III HIV vaccine trials among South African adolescents requires investigation. 
1A.2 Knowledge of HIV vaccines and HIV vaccine trial processes 
There is a vast amount of research that has assessed k.'1owledge of HIV vaccines and HIV vaccine 
trial methodology among specific samples (e.g.: MacQueen et aI., 1999; McGrath et aI., 2001; Strauss et aI., 
2001). Results of these studies have consistently shown a lack of knowledge regarding HIV vaccines and 
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HIV vaccine trial methodology. Additionally, numerous studies have investigated the association between 
knowledge of HIV vaccines, HIV vaccine trial methodology and WTP in HIV vaccine trials among various 
samples (e.g.: Halpern, Metzger, Berlin, & Ubel, 2001; Kiwanuka et a1., 2004; Koblin et a1., 2000; O'Connell 
et al., 2002; Priddy, Cheng, Salazar, & Frew, 2006; Sahay et aL, 2005; Smit et aL, 2006; Starace et al., 2006). 
The findings of these studies are mixed. \Vhile some studies have found that WTP in an HIV vaccine trial 
was significantly higher in participants with a greater knowledge about HIV vaccines and HIV vaccine trials 
(e.g.: Sahay et al., 2005; Starace et a1., 2006), other studies have found that knowledge was not significantly 
associated with WTP in an HIV vaccine trial (e.g.: Priddy et al., 2006). In addition, some studies have found 
that the acquisition of new knowledge regarding HIV preventative vaccine tlials may lead to a paradoxical 
decrease in WTP in these trials (Kob1in et al., 2000). 
In South Africa, previous research focusing on WTP in an HIV vaccine trial has been of little utility 
as South African participants have frequently shown low levels of knowledge of HIV vaccine trials and what 
enrolment in these trials entails (Smit et a1., 2006). This lack of understanding and knowledge of HIV 
vaccines and HIV vaccine trials indicates a need to assess knowledge levels among South African 
adolescents and to determine the relationship (if any) between this construct and WTP in a future Phase III 
HIV vaccine trial. 
1.4.3 Attitudes toward HIV/AIDS 
There is extensive international research conducted on attitudes toward HIV I AIDS. There is however 
a lack of research focusing on adolescent attitudes toward HIV IAIDS in South Africa. Moreover, there is a 
paucity of research specifically focusing on the relationship between attitudes toward HIV IAIDS and WTP in 
an HIV vaccine trial among adolescents. There is however evidence that negative attitudes toward HIV I AIDS 
persist in South Africa and these attitudes have been cited as an inhibitor to HIV vaccine trial participation 
(Lesch, Kafaar, Kagee, & Swartz, 2006). The relationship between attitudes toward HIV/AIDS and WTP in 
an HIV vaccine trial among South African adolescents requires assessment. 
1.4.4 Health-promoting behaviours 
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There is no research which explicitly describes and predicts the relationship between health-
promoting behaviours and \VTP in an HIV vaccine trial among adolescents. Prior research has focused on the 
relationship between health behaviours and the acceptance of a hypothetical HIV preventative vaccine (Liau 
& Zimet, 2000; Zimet, Fortenbeny, & Blythe, 1999) and the relationship between health behaviours and 
WTP in HIV preventative intervention programs (Yang et a1., 2004). Given that these studies are vastly 
unrelated to \VTP in a future HIV vaccine trial, the relationship bctween health-promoting behaviours and 
\viP in an HIV vaccine trial among adolescents awaits investigation. 
lA.5 Theoretical framework 
There is a paucity of theoretical work conducted around vVTP in an HIV vaccine trial. Moreover, 
there is skepticism around the extent to which conventional theories can be used to explain a complex 
construct such as \VTP in an HIV vaccine trial. Nevertheless, a social cognitive model that has been shovvn to 
predict behavioral intentions and overt behaviours is the Theory of Planned Behaviour (TPB) developed by 
Ajzen (1988). The TPB has been used to assess a variety of behaviours including health-related behaviours 
such as testicular self-examination (e.g.: Brubaker & Wickersham, 1990), clinical glove use (e.g.: Watson & 
Myers, 2001), treatment adherence in various populations (e.g.: Conner, Black, & Stratton, 1998; Povey, 
Conner, Sparks, James, & Shepherd, 2000), HIV preventative behaviours (e.g.: Albanacin, Johnson, 
Fishbein, & Muellerleile, 2001; Boer & Mashamba, 2005; Giles, Lidell, & Bydawell, 2005; McCabe & 
Killackey, 2004) as well as intentions to receive various vaccinations (e.g.: de Wit, Vet, Schutten, & van 
Steenbergen, 2004; Gagnon & Godin, 2000). However, a review of the literature revealed that no studies 
both internationally and within South Africa have used the TPB to predict WTP in an HIV vaccine trial. 
Although participation in an HIV vaccine tlial is not conventionally regarded as a health behaviour, 
from the perspective of a participant, receiving a vaccine in the context of a trial may increase the likelihood 
of protection from HIV infection above that of an individual who does not participate in an HIV vaccine trial. 
Therefore, trial participation is framed as a health behaviour with the expectation that protection from 
infection may follow (Kafaar, Kagee, Lesch, & Swartz, 2006). In light of the above prospect, it may be 
useful to apply existing theories of health behaviour to gain an understanding of\VTP in future Phase III HIV 
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vaccine trials. The application of existing theoretical models can aid social scientists to engage in a process 
of theory-testing and theory-building (Kafaar et al., 2006). The ability of the TPB to predict \VTP in future 
phase III HIV vaccine trials among South Aflican adolescents therefore requires assessment. 
1.5 Definition of adolescence 
6 
The critetia for the beginning of adolescence are clear and defined. However, the question of when 
this period typically ends is challenging and less concrete. Newman and Newman (1999) subdivided 
adolescence into two periods, namely, early adolescence and late adolescence. Early adolescence begins with 
the onset of puberty and ends at the completion of secondary school education (or roughly at 18 years of 
age). Late adolescence begins at approximately 18 years of age and continues for approximately six years 
(roughly at 24 years of age). Meyer (2004a) defines late adolescence as typically stretching between 18 and 
22 years of age. The longer adolescent period in Western culture is the result of an earlier onset of puberty, 
prolonged financial dependency on parents and relatively lengthy education and training (Meyer, 2004b). 
Therefore, following the guidelines offered by Ne\vman and Newman (1999) and Meyer (2004a, 2004b), 
adolescence, in the present study, is regarded as a period typically ending at approximately 22 years of age. 
Consequently, all participants younger than 22 years of age were included in the present study. 
1.6 Objectives of the present study 
The first objective of the present study was to detennine whether the TPB could significantly predict 
WTP in future Phase III HIV vaccine trials among high risk adolescents in the Western Cape. The second 
objective of the present study was to determine whether the inclusion of additional predictor variables (Self-
perceived risk of HIV infection, Knowledge of HIV vaccines and HIV vaccine trials, Attitude towards 
HIV/AIDS and Health-promoting behaviours) could further explain WTP in future Phase III HIV vaccine 
trials among high risk adolescents in the Western Cape. 
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CHAPTER 2 
LITERATURE REVIE\V AND THEORETICAL FRAME\VORK 
The objective of the present study was to determine whether the TPB could significantly predict WTP in 
future Phase III HIV vaccine trials among high risk adolescents in the Western Cape. The second objective of 
the present study was to determine whether the additional predictor variables of Perceived risk of HI V 
infection, Knowledge of HIV vaccines and HIV vaccine trials, Attitudes toward HIV IAIDS and Health-
promoting behaviours could further explain WTP in future Phase III HIV vaccine trials among high risk 
adolescents in the ~Western Cape. In this chapter, the existing literature around each predictor variable 
included in the present study will be reviewed. Subsequently, the theoretical model used in the present study 
will be explained and discussed. 
2.1 Perceived risk of HIV infection 
Perceived risk of HIV infection is consistently shown to be a significant predictor of WTP in HIV 
vaccine trials among various samples. For example, among young Thai men (e.g.: Jenkins et al., 2000), 
i~merican samples (e.g.: Johnson, 2000), Ugandan samples (e.g.: Kiwanuka et ai., 2004; McGrath et at, 
2001), low-socioeconomic communities in America (e.g.: Nevrman et ai., 2006), young gay and bisexual 
men in Canada (e.g.: O'Connell et al., 2002), men who have sex with men (MSM) in Brazil (e.g.: Perisse et 
al., 2000), Indian samples (e.g.: Sahayet al., 2005), London gay men (e.g.: Shen et al., 2004) and finally, 
Italian samples (e.g.: Starace et aI., 2006). 
In the South African context, Smit et al. (2006) rep0l1ed that in a sample of 16-40 year old 
participants, seif-perceived HIV risk was significantly associated with WTP in an HIV vaccine trial. 
Although numerous studies have rep0l1ed a significant relationship between perceived HIV risk and \VTP in 
an HIV vaccine trial in specific samples, there is a paucity of research focusing on this relationship among 
South African adolescents. Therefore, the relationship between self-perceived risk of HIV infection and \VTP 
in future Phase III HIV vaccine trials among South African adolescents requires further investigation. 
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2.2 Knowledge of HIV vaccines, HIV vaccine trials and related concepts 
Numerous studies conducted on \VTP in HIV vaccine trials have assessed knowledge of HIV 
vaccines and knowledge of HI V vaccine trial methodology (e.g.: MacQueen et a1., 1999; McGrath et aI., 
2001; Strauss et aI., 2001). Results of these studies have shown a lack of knowledge regarding HIV vaccines 
and HIV vaccine trial methodology among participants. 
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In a study conducted on WTP in an HIV vaccine trial among injection drug users (IDUs) in Thailand, 
MacQueen et a1. (1999) assessed changes in participants' knowledge of an HIV vaccine trial over a week. 
Results showed that knowledge was high at baseline and improved at foHow-up for the majority of 
participants. However, there were participants VJho had low knowledge levels. The results showed that 
participants did not understand that an HIV vaccine is preventative rather than curative. Moreover, 
participants did not understand concepts relating to HIV vaccine trial methodology such as double blinding 
procedures (MacQueen et aI., 1999). Continuing educational efforts should be made to ensure that low 
knowledge levels and little scientific literacy to understand HIV vaccine trial methodology do not prevent 
participation in future HIV vaccine trials. 
McGrath et a1. (2001) found that the majority of participants in a Ugandan sample were familiar with 
the HIV vaccine but did not clearly understand whether the HIV vaccine that they were informed about was 
preventative or curing in function. Moreover, the participants were not knowledgeable about vaccine trial 
methodology such as a placebo control group, randomisation, and blinding procedures. 
Strauss et a1. (2001) assessed WTP in an HIV vaccine trial among three US communities. The 
majority of participants emphasised the need for jnfonnation regarding the HIV vaccine, HIV vaccine trial 
methodology and processes that would be followed in an HIV vaccine trial. Participants required knowledge 
and understanding of issues relating to confidentiality, possible health complications, assistance/support in 
dealing with these complications, incentives that would be offered to compensate for participation, the 
effectiveness of the vaccine and future availability of the vaccine. Moreover, participants emphasised the 
need for infonnation and education regarding vaccine trial methodology such as experimental versus placebo 
control groups (Strauss et aI., 2001). The desired information reported by participants highlights the need to 
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educate communities and potential trial participants about the HIV vaccine trial process. Educational 
initiatives may improve understanding of HIV vaccine trials in communities at risk for HIV / AIDS. 
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The lack of knowledge regarding the HIV vaccine and HIV vaccine trial methodology raises the 
concern that potential trial participants who do not understand how the vaccine trial works and the related 
uncertainty of the trial process may decrease efforts to reduce high risk behaviours or increase engagement in 
high risk behaviours (Koblin, Avrett, Taylor, & Stevens, 1997). Strauss et al. (2001) argue that educating 
communities about the implementation of Phase III HIV vaccine trials is not only crucial for the conduct of 
ethically sound research, but is critical to the process of developing a safe and effective vaccine to help 
control the HIV pandemic worldwide. 
2.2.1 Informed consent 
Linked to knowledge of HIV vaccines and HIV vaccine trial methodology are ethical considerations 
such as the process of infonned consent. Volunteers in a Phase III HIV vaccine trial are required to provide 
infonned consent before enrolment in such a trial (Lindegger & Richter, 2000). Individuals require a 
complete understanding of the utility of HIV vaccines as well as the risks and benefits involved in 
participating in an HIV vaccine trial. There are many potential risks associated with HIV vaccine trials and 
participants may not entirely appreciate their implications (Koblin et al., 2000). Moreover, an important 
aspect of obtaining true informed consent from trial participants requires an ability to fully understand the 
various technical aspects and procedures of the HIV vaccine trial (Lindegger et al., 2000). In the event of 
high levels of illiteracy, individuals may not fully understand vaccine trial processes and concepts and 
subsequently be drawn into participating by free medical benefits or monetary compensation (Lindegger et 
ai., 2000). It is therefore an imperative that potential participants' knowledge of HI V vaccines and HIV 
vaccine trial procedures undergo assessment before the onset of Phase III HIV vaccine trials in order to 
ensure ethically, legally and scientifically valid research, as well as the eventual development of a safe and 
effective vaccine to control the HIV epidemic. 
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2.2.2 Knowledge of HIV vaccines and WTP in an HIV vaccine trial 
There are numerous studies that have assessed the association between knowledge of HIV vaccines, 
HIV vaccine trials and WTP in an HIV vaccine trial (e.g.: Halpern et al., 2001; Kiwanuka et al., 2004; Koblin 
et al., 2000; O'Connell et al., 2002; Priddy et al., 2006; Sahayet a1., 2005; Smit et al., 2006; Starace et al., 
2006; Lesch et al., 2006). While some studies have found that knowledge of HIV vaccines was not associated 
with WTP in an HIV vaccine trial (Halpern et al., 2001; Priddyet aL, 2006), other studies have found a 
significant relationship between knowledge of HIV vaccines and WTP in an HIV vaccine trial (Kiwanuka et 
al., 2004; Koblin et al., 2000; Sahay et al., 2005; Smit et aI., 2006; Starace et al., 2006).The results of these 
studies are discussed in tum. 
Halpern et al. (2001) assessed changes in the stated WTP in, and knowledge of a hypothetical HIV 
vaccine trial among a sample in Philadelphia over an 18-month period. Following educational initiatives 
aimed at promoting increased knowledge of HIV vaccines and vaccine trials, results showed an increase in 
HIV vaccine knowledge at follow up. However, this increase in knowledge was not significantly associated 
with V/TP in an HIV vaccine trial. However, a limitation of this study was that several items appearing on 
the knowledge questionnaire used to identify participants' understanding of trial concepts were used 
repeatedly at testing sessions. Therefore, this assessment may have represented participants' familiarity with 
the measuring instrument rather than a true assessment of HIV vaccine knowledge. 
In a study assessing racial and etlmic differences in WTP in an HIV vaccine trial among college 
students in the US, Priddy et al. (2006) found that knowledge of HIV vaccines was not significantly 
associated with WTP in an HIV vaccine trial. 
Kiwanuka et al. (2004) investigated knowledge of HIV vaccines and WTP in HIV vaccine trials among 
adolescents and adults in Uganda. Following a community education program, awareness of HI V vaccines 
increased to 81 % compared to 68% at baseline (Kiwanuka et al., 2004). Knowledge that the HIV vaccine is 
preventative in function was relatively high in the sample (71 %) and higher in men than in women 
(Kiwanuka et al., 2004). However, the majority of participants, including more than half of the men believed 
that only women and children are eligible to receive an HIV vaccine once it becomes available. Moreover, 
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93.7% of the sample believed that adolescents are most eligible to participate in an HIV vaccine trial 
(Kiwanuka et al., 2004). The beliefthat adolescents are most eligible for HIV vaccine trial enrolment is 
problematic as it may influence adult participation in future HIV vaccine trials (Kiwanuka et aL, 2004). More 
than half the participants (60.2%) believed that HIV-positive individuals are eligible for participation in HIV 
vaccine trials and only 20% believed that the HIV vaccine can control HIV (Kiwanuka et aL, 2004). 
Willingness to participate in an HIV vaccine trial was assessed at follow up and was 77% (Kiwanuka et al., 
2004). However, a limitation of this study is that WTP was only measured at the follow up survey. The data 
do not contain pre-test measures of \VTP in an HIV vaccine triaL As a result of this flaw, it is not feasible to 
conclude that an increase in HIV vaccine knowledge led to an increase in WTP in HIV vaccine trials. In fact, 
the acquisition of new knowledge regarding HIV preventative vaccine trials may have led to decreased \VTP 
in an HIV vaccine trial. 
This possibility is supported by the findings of Koblin et a1. (2000). Changes in HIV vaccine knowledge 
and WTP in an HIV vaccine trial were assessed in a high risk sample of gay men (MSM), male and female 
injection drug users (IDU) and non-injecting women at heterosexual risk (WAHR) for a period of 18 months. 
Knowledge levels increased for all study populations by the 18-month visit. However, results showed a lack 
of knowledge concerning the possible effects of the vaccine on the immune system and the effectiveness of 
the vaccine at the start of a trial (Koblin et aL, 2000). An increase in HIV vaccine knowledge was 
significantly associated with WTP in an HIV vaccine trial among certain subpopulations. However, among 
MSM men with low knowledge levels, an increase in knowledge about HIV vaccines was significantly 
associated with becoming unwilling to participate in HIV vaccine trials. This finding implies that vVTP 
among individuals with higher knowledge levels is likely to remain unchanged with the acquisition of further 
knowledge regarding HIV vaccine trials. On the contrary, a paradoxical decrease in WTP among those with 
low knowledge levels is likely to occur with acquiring new knowledge regarding HIV vaccine trials (Koblin 
et aI., 2000). 
Similarly, O'Connell et a1. (2002) assessed the changes in WTP between a hypothetical HIV vaccine trial 
and an HIV vaccine trial offered in the period of the ongoing AIDSVi\X BIB phase III trial in Vancouver, 
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Canada. The results showed that \\tiP decreased between 1997 and 2001. Although stated willingness to 
participate in a hypothetical trial does not guarantee enrolment into an actual trial, O'Connell et al. (2002) 
argue that this decline in WTP may have been driven by an increase in awareness or understanding of HIV 
vaccine trial concepts and potential implications of participation in an actual HIV vaccine trial. 
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Conversely, Sahayet al. (2005) assessed the correlates of HI V vaccine trial participation in an Indian 
sample. The results of this study showed that the majOlity of the participants were aware of the seriousness of 
the HIV pandemic and were familiar with the term "vaccine". However, less than half of the participants 
were aware of the ongoing struggle for developing an effective HIV vaccine. Although only a small number 
of participants were aware that the HIV vaccine is preventive in function, no participants felt that the HIV 
vaccine would be completely ineffective. Consistent with the findings of Kiwanuka et al. (2004), many 
participants were unaware of adult participation in HIV vaccine trials. Participants who were familiar with 
the HIV vaccine and who had a greater understanding of the function of an HIV vaccine were significantly 
more willing to participate in an HIV vaccine trial (Sahay et al., 2005). Moreover, participants with a better 
awareness of the current efforts to develop an effective HIV vaccine and belief in the success of the HIV 
vaccine were significantly more willing to participate in an HIV vaccine tria! (Sahay et al., 2005). 
Starace et al. (2006) assessed knowledge of HI V vaccine trials among an Italian sample. Results showed 
that over 50% of the sample had an adequate knowledge about HIV vaccines and HIV vaccine trial 
processes. Moreover, WTP in an HIV vaccine trial was significantly higher in participants with a greater 
knowledge about HIV vaccines and HIV vaccine trials. 
In the South African context, Smit et a1. (2006) assessed WTP in an HIV vaccine trial among 16-40 year 
old participants. Similar to the findings of Sahay et a1. (2005) and those of Starace et a1. (2006), increasing 
knowledge of HIV vaccines was significantly associated with WTP in an HIV vaccine trial. Results showed 
that an increase of one unit in HIV vaccine knowledge scores was associated with a 10 fold increase in \VTP 
in HIV vaccine trials respectively (Smit et ai., 2006). Nonetheless, despite this significant finding, more than 
70% of the participants in this study emphasised the need for more infonnation regarding the HIV vaccine 
and HIV vaccine trials in order for them to answer questions related to vVTP in an HIV vaccine trial. 
Stellenbosch University  http://scholar.sun.ac.za
13 
Therefore, prospective trial participants lack knowledge about HIV vaccine trials and have limited 
scientific literacy to understand HIV vaccine trial methodology. This lack of knowledge may be a crucial 
factor affecting potential participants' decision to participate in an HIV vaccine tlial. Therefore, while WTP 
in an HIV vaccine trial is relatively low in this sample, educational initiatives may be crucial in impacting on 
individuals' WTP in HIV vaccine trials (Smit et aI., 2006). A possible limitation of this study is that the 
questionnaires used were derived from international sources and were therefore not validated in South 
African samples. It is therefore a possibility that that the high rate of non-responses from pm1icipants was not 
due to a lack of HIV vaccine knowledge but because questions did not tap into salient concerns of the South 
African population. 
Similarly, Lesch et al. (2006) qualitatively assessed WTP in an HIV vaccine trial in a South African 
sample. Research participants emphasised the need for information and education regarding HIV vaccines 
and HIV vaccine trials for themselves and community members. Moreover, the pm1icipants reported that a 
lack of information and education regarding HIV vaccines and HIV vaccine trials may act as a potential 
inhibitor to participation in an HIV vaccine trial (Lesch et aL 2006). Therefore, further assessment among 
South African samples is required in order to identify the infonnation that potential trial participants require 
in order to make a decision about trial participation. 
2.3 Attitudes toward HIV IAIDS 
As stated by Parker and Aggleton (2003) negative social responses to the HIV epidemic remain 
pervasive in communities, even in those seriously affected by HIV/AIDS. These negative social responses to 
HIV IAIDS impede efforts aimed at promoting voluntary counseling and testing and other HIV / AIDS 
prevention efforts (Kalichman & Simbayi, 2004). Consequently, there has been a great deal of focus on HIV 
and AIDS-related stigma and discrimination. Moreover, much of the empirical research that has been 
conducted on HIV and AIDS-related stigma has focused on the beliefs and attitudes of those who are 
perceived to stigmatise individuals affected by HIV!AIDS. There has been a specific focus on negative 
attitudes toward groups who are believed to be excessively affected by the epidemic, for example: gay and 
bisexual men, injecting drug users and sex workers (Herek, Capitanio, & Widaman, 2002). Moreover, 
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attitudes toward HIV/AIDS have been extensively investigated in numerous other international 
populations such as nurses and health care professionals (e.g.: Tierney, 1995), medical students (e.g.: Li & 
Cole, 1993) and various adult samples (e.g.: BaH, Waring, & Warshaw, 1992; Roberts & Blakey, 1994). 
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Fears, misconceptions and negative attitudes toward individuals with HIV I AIDS are common 
(Valimaki, Suominen, & Peate, 1998). There is a great deal of confusion about the nature of HI V and 
cynicism towards those perceived as exhibiting high-risk behaviours (Roberts & Blakey, 1994). IIlV 
infection is frequently regarded as a punitive consequence of a sexually promiscuous lifestyle (Redjimi & 
Lert, 1993). Among a sample of medical students, Li and Cole (1993) found that many of the participants 
believed that prostitutes, drug addicts and homosexuals are to blame for AIDS and people living with AIDS 
got what they deserve (Li & Cole, 1993). Attitudes toward HIV/AIDS have been highly resistant to change 
(Valimaki et al., 1998) and education has been identified as a key determinant to improving knowledge of 
and attitudes toward HIV / AIDS. 
Brook (1999) assessed attitudes toward HIV/AIDS among a sample of 1724 adolescents attending 
three different urban high schools (academic, vocational and religious) in Israel. The three samples were 
diverse and varied in their socio-economic status, education and family status (Brook, 1999). Attitudes 
toward HIV I AIDS and people living with HIV I AIDS were diverse. Results showed that pupils attending the 
academic high school were most tolerant toward HIV/AIDS and people living with HIV/AIDS than the 
pupils attending the vocational high school. Pupils attending the religious school were most conservative and 
intolerant toward HIV/AIDS. Only one third of the adolescents surveyed stated a willingness to volunteer in 
medical and rehabilitation centers devoted to helping HIV / AIDS patients (Brook, 1999). The learners stated 
that all pupils should be made aware of HIV positive pupils attending the school. Several of the pupils stated 
that an HIV positive student should be banned from school completely (Brook, 1999). The adolescents 
acknowledged that they prefeHed not to sit next to a fellow student who was HIV positive. Additionally, 
numerous students stated that they would discontinue any relationship with a friend who was diagnosed HIV 
positive. They stated that keeping a diagnosis of HIV! AIDS in confidence should be avoided. The majority of 
pupils received infonnation regarding HIV/AIDS from television and the media. The adolescents reported 
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that physicians and nurses in clinics and schools were in last place for teaching students about HIV! AIDS 
(Brook, 1999). This finding provides motivation for more comprehensive and systematic HIV/AIDS 
instruction in schools and clinics and may contribute to more tolerant attitudes toward HIV! AIDS and 
individuals living with HIV I AIDS. 
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Similarly, Dias, Matos, and Gon~alves (2006) assessed adolescent attitudes toward HIV IAIDS in 
Portugal. Results showed that the majority of adolescents were tolerant toward HIV/AIDS and people living 
with HIV I AIDS. The majority of adolescents acknowledged the stigma, discrimination and social exclusion 
experienced by HIV-infected individuals. The adolescents stated that HIV-infected individuals are frequently 
avoided due to a lack of adequate knowledge about HIV transmission and a fear of contracting HIV. 
Moreover, half of the adolescent sample reported feeling compassionate toward HIVI AIDS patients (Dias et 
al., 2006). On the contrary, several adolescents were intolerant toward HIV/ AIDS. Some adolescents 
reported fears of HIV -infected people, acknowledged that they would avoid an infected individual and feel 
oppressed if they were in the same room as an HIV-infected individual (Dias et a1., 2006). Similar to the 
findings of Brook (1999), information regarding HIV/AIDS was mostly obtained from the mass media. 
Adolescents stated that information regarding the social and mental probiems associated with HIVI AIDS had 
never been discussed at school CDias et al., 2006). This finding poses a problem as inaccurate and negative 
attitudes toward HIV I AIDS may encourage fear and discrimination. In tum, this may perpetuate the stigma 
associated with HIV I AIDS and therefore create a ban-ier to HIV testing and prevention (Klein, Karchner, & 
O'Connell,2002). 
Numerous other studies have assessed attitudes toward HIV / AIDS among various adolescent samples 
internationally (e.g.: Agrawal, Rao, Chandrashekar, & Coulter, 1999; Katz, Mills, Singh, & Best, 1995; Levy 
et ai., 1995; Savaser, 2003; Yong & Miller, 1993; Zimet et al., 1993). Ambivalent attitudes toward 
HIV I AIDS are common among adolescents and results consistently indicate a need for education in order to 
promote accurate knowledge about HIV/AIDS and tolerant attitudes toward HIV/AIDS. 
According to Kalichman and Simbayi (2004) HIV and AIDS-related stigma is pervasive in South 
African communities. There is however a lack of research focusing on adolescent attitudes toward HIV / AIDS 
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in South Africa. Moreover, a review of the literature revealed no research directly focusing on the 
association between attitudes toward HIV / AIDS and WTP in an HIV vaccine trial among adolescents. 
Nonetheless, in a recent study conducted among South African community members, participants reported 
that the HIV vaccine's association with HIV/AIDS may be a potential limitation to HIV vaccine trial 
participation (Lesch et aI., 2006). Moreover, pm1icipants reported that there is a pervasive negative 
perception of HIV IAIDS within South African communities (Lesch et aI., 2006). Individuals are therefore 
ambivalent and cautious toward anything which may be HIV-related (Lesch et aI., 2006). 
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Similarly, Allen et a1. (2001) found that volunteers in an HIV vaccine trial reported experiencing 
negative reactions from friends, family and co-workers following self-disclosure oftrial participation. For 
some of the volunteers, these negative reactions were related to the vaccine's association with HIV/AIDS. As 
stated by Rudy et a1. (2005) there are many misconceptions about HIV I AIDS and preventative vaccines. 
There is a great tendency for HIV to be thought of as a gay disease and individuals consequently fear being 
labeled gay, promiscuous and engaging in risky behaviours (Rudy et aI., 2005). Therefore, the risk of being 
stigmatised and discriminated against may influence potential pm1icipants' final decision to participate in an 
HIV vaccine trial. Allen et a1. (2005) suggest that attitudes toward HIV / AIDS vary by population and that 
these attitudes need to be addressed in order to ensure an adequate number of volunteers for future HIV 
vaccine trials. 
2.4 Health-promoting behaviours 
As reported by Kulbok and Cox (2002) the Centers for Disease Control and Prevention have reported 
that health-risk behaviours such as unprotected sexual relations, substance abuse, poor diet, reduced physical 
activity, reckless driving, failure to use seatbelts and violence significantly contribute to adolescent morbidity 
and mortality. Moreover, as suggested by Zhuravleva (2001) health behaviours have become increasingly 
important with the dramatic increase in individuals' susceptibility to diseases such as HIVI AIDS, particularly 
among adolescents and young adults. 
Prior research has focused on the relationship between certain health beliefs (such as self-perceived 
risk of HIV infection) and the acceptance of a hypothetical HIV preventative vaccine (Liau & Zimet, 2000; 
Stellenbosch University  http://scholar.sun.ac.za
Liau, Zimet, & Fortenberry, 1998; Zimet, Liau, & Fortenberry, 1997). Additionally, past research has 
assessed the relationship between health behaviours and the acceptance of a hypothetical HIV preventative 
vaccine (Liau & Zimet, 2000; Zimet et ai., 1999). Research has also investigated the association between 
health behaviours and \VTP in HIV preventative intervention programs (Yang et aI., 2004). 
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In the study conducted by Yang et al. (2004), results showed that participants who were not willing to 
paIiicipate in HIV preventative programs were more likely to engage in health-compromising behaviours. 
Health-promoting behaviours were signiilcantly related to WTP in HIV prevention programs. Those 
participants who were more willing to participate tended to engage in more health-promoting behaviours 
(Yang et aJ., 2004). 
Zimet et al. (1999) found that increased engagement in health-risk behaviours was associated with 
greater HIV vaccine acceptance among adolescents. Moreover, health-promoting behaviours were not 
associated with greater HIV vaccine acceptance among the adolescent sample. Therefore, contrary to the 
expectation that a hypothetical HIV vaccine would be less accepted among individuals engaging in high risk 
behaviours, the adolescents engaging in health-risk behaviours were accepting of the hypothetical HIV 
vaccine and showed a heightened interest in the potential protection associated with being vaccinated (Zimet 
et aI., 1999). 
Conversely, Liau and Zimet (2000) assessed hypothetical HIV vaccine acceptability among university 
undergraduates aged 18 years and older. The results showed that less engagement in health-risk behaviours 
was associated with increased HIV vaccine acceptance for the entire sample. This finding supports the 
hypothesis that engagement in certain health-compromising behaviours may lead to decreased hypothetical 
HIV vaccine acceptance (Liau & Zimet, 2000). 
The results of these studies suggest that certain health behaviours are likely to influence an 
individual's decision regarding HIV vaccination or participation in HIV prevention programs. The 
acceptance of a hypothetical HIV preventative vaccine and \VTP in HIV preventative intervention programs 
is vastly unrelated to participation in an HIV vaccine trial and is therefore beyond the scope of interest in the 
present study. However, a review of the literature revealed that there are no studies which explicitly describe 
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and predict the relationship between health-promoting behaviours and WfP in an HIV vaccine trial among 
adolescents. This relationship (if any) therefore awaits investigation among South African adolescents. 
2.5 Demographic characteristics 
A review of the literature revealed that aithough the majority of studies assessing WTP in HIV 
vaccine trials have incorporated a variety of demographic characteristics, not all of these studies have found a 
significant relationship between these variables and WTP in an HIV vaccine trial. The findings of these 
studies are mixed and are discussed in turn. 
2.5.1 Age 
\Vhile some evidence suggests that age is not related to WfP in an HIV vaccine trial (e.g.: Jenkins et 
aI., 2000; Kiwanuka et aI., 2004; McGrath et aI., 2001; Viera De Souza, Lowndes, Szwarcwald, Sutmoller, & 
Bastos, 2003), it has been reported that age is significantly related to WTP in an Hrv vaccine trial (e.g.: 
Bartholow et aI., 1997; Buchbinder et al., 2004; Jenkins et aI., 1998; Koblin et aI., 1997; O'Connell et aI., 
2002; Smit et aI., 2006). Some studies have reported that younger age is significantly associated with \VIP in 
an Hrv vaccine trial (Buchbinder et aI., 2004; Jenkins et ai., 1998; O'Connell et aI., 2002), and others have 
reported that increasing age is significantly associated with WTP in an HIV vaccine trial (Bartholow et aI., 
1997; Koblin et al., 1997; Smit et aI., 2006). 
2.5.2 Gender 
While some studies have reported that gender is not related to WTP in an HIV vaccine trial 
(Kiwanuka et aI., 2004; Sahay et aI., 2005), it has been reported that a significant relationship between 
gender and \VTP in an HIV vaccine trial does exist (e.g.: Jenkins et at, 1998; Smit et aI., 2006). The studies 
conducted by Jenkins et al. (1998) and Smit et al. (2006) found males to be more willing to participate in an 
HIV vaccine trial. 
2.5.3 Education 
Some researchers have not found a significant relationship between education level and WTP in an 
HIV vaccine trial (e.g.: Kiwanuka et aI., 2004), however some have repOlied a relationship between 
education and WTP in an HIV vaccine trial (e.g.: Jenkins et al., 2000). Jenkins et al. (2000) repOlied that 
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participants who were relatively well educated were more WTP in an HIV vaccine trial. Conversely, 
Peri sse et al. (2000) reported that a low level of education was positively associated with \VTP in an HIV 
vaccine triaL Consistent with this finding is those of Bartholow et al. (1997) and Viera De Souza et aL 
(2003). 
2.5.4 Race 
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Although some studies have not reported a significant association between race and \VTP in an HIV 
vaccine trial (e.g.: Viera De Souza et aI., 2003), there is evidence that race is significantly associated with 
WTP in an HIV vaccine trial (e.g.: Bartholow et aI., 1997; Buchbinder et ai., 2004; Halpern et aI., 2001). 
2.6 Theoretical Framework 
The Theory of Reasoned Action (TRA) (Fishbein & Ajzen, 1975) and the Theory of Planned 
Behaviour (TPB) (Ajzen, 1988) are theories commonly used to understand numerous behaviours including 
health-related behaviours. The TRA was first introduced to the literature at the crucial period when the 
relationship between attitudes and behaviour was under increasing scrutiny (Ajzen & Fishbein, 1980). The 
TRA deals with the relationship between beliefs, attitudes, intentions and behaviour and is based on the 
assumption that human beings are rational in their decision making and make logical use of information 
available to them (Ajzen & Fishbein, 1980). The TR.A. postulates that human social behaviour is not 
controlled by unconscious motives, nor is it a thoughtless process. Instead, individuals consider the 
implications of their actions before engaging in a specific behaviour (Ajzen & Fishbein, 1980). 
According to the TRA, the key detenninant of behaviour is an individual's intention to perform or not 
perform the specific behaviour (Ajzen & Fishbein, 1980). Moreover, an individual's intention to perform a 
specific behaviour is a function of two variables, namely: the individual's attitude toward the behaviour and 
the individual's perception of existing subjective nonns concerning the behaviour (see Figure 1). Attitudes 
toward the behaviour and Subjective norms concerning the behaviour are comprised of infonnation or beliefs 
relevant to the patiicular behaviour (Ajzen, 1988). Therefore, attitudes toward the behaviour include the 
individual's positive or negative evaluation of perfonning the behaviour. These attitudes are a function of 
behavioural beliefs concerning the particular behaviour (Ajzen & Fishbein, 1980). An individual who 
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believes that performing the behaviour will lead to positive outcomes will hold a favourable attitude 
toward performing the behaviour. Conversely, an individual who believes that performing the behaviour will 
lead to negative outcomes will hold an unfavourable attitude toward performing the target behaviour (Ajzen 
& Fishbein, 1980). Subjective norms concerning the behaviour include an individual's perception of existing 
social pressure to perfoffil or not perfonn the target behaviour (Ajzen & Fishbein, 1980). Subjective nonns 
concerning the behaviour are a function of normative beliefs (Ajzen & Fishbein, 1980). An individual who 
believes that significant others think he/she should perform the behaviour will perceive social pressure to do 
so. Conversely, an individual who believes that significant others think he/she should not perform the target 
behaviour will perceive social pressure to avoid the behaviour (Ajzen & Fishbein, 1980). 
The individual's 
beliefs that the Attitude 
behaviour1eadsto towards the 
certain outcomes and behaviour 
his/her evaluations of 
these outcomes \ 
Intention f-4 
Behaviour 
The individual's / beliefs that specific individuals/ groups 
think he/she should Subjective 
perform the behaviour nonllS 
and his/her motivation 
to comply with these 
individuals/ groups 
Figure I. Components of the Theory of Reasoned Action (Ajzen & Fishbein, 1980). 
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2.6.1 The Theory of Planned Behaviour (TPB) 
The TPB (Ajzen, 1988) is an extension of the TRA and is directed at behaviours which may not be 
under the complete control of the individual (Ajzen, 1988). External obstacles and a lack of adequate 
resources can interfere with the performance of any behaviour (Ajzen, 1988). Therefore, a behavioural 
intention can best be understood as an individual's willingness to attempt performing a given behaviour. The 
performance ofthe intended behaviour relies on the individual's control over various factors that may impede 
it (Ajzen, 1988). 
The difference between the TRA and the TPB is the inclusion of a third variable, alongside Attitudes 
and Subjective norms 1 which acts as an additional determinant of an individual's intention to perfonn a 
specific behaviour. This variable is Perceived Behavioural Control (PBC) and refers to an individual's 
evaluation of the realistic constraints that may exist (such as the ease or difficulty of perfonning the 
behaviour) and the external factors that may playa role (such as available resources and anticipated 
obstacles) (Ajzen, 1988). An individual's PBC is a function of control beliefs concerning the particular 
behaviour (Ajzen, 1988). If an individual believes that he/she has requisite resources and opportunities to 
perform the behaviour and anticipates few impediments, the greater their perceived behavioural control over 
the target behaviour (Ajzen, 1988). The TPB postulates that the key detenninant of an individual's behaviour 
is his/her intention to perform the target behaviour. Behavioural intention is a product of three determining 
factors: an individual's attitude towards performing the behaviour, an individual's perception of social 
pressure to perfonn the behaviour and lastly, an individual's perceived capacity to perform the behaviour 
(see Figure 2). Overall, the theory postulates that the more positive the attitude toward the behaviour, the 
more positive the subjective norms concerning the behaviour and the greater the perceived behavioural 
control over the behaviour, the stronger the individual's intention to perfonn the behaviour (Ajzen, 1988). In 
addition, Ajzen (1988) suggests that PBC holds a motivational function for intentions. Therefore, behaviour 
can be directly influenced by PBC, without the mediating effects of Attitudes toward the behaviour and 
Subjective norms concerning the behaviour. Consequently, if an individual believes that he/she has neither 
I Subjective nom1S may be used interchangeably with perceived group nonns 
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the resources nor the opportunity to perform the behaviour, he/she is unlikely to hold strong behavioural 
intentions, regardless ofhis/her attitudes toward the behaviour or his/her perception of existing social 
pressure to perfonn the given behaviour. 
The individual's 
beliefs that the 
behaviour leads to 
certain outcomes and 
his/her evaluations of 
these outcomes 
The individual's 
beliefs that specific 
individuals/groups 
think he/she should 
perform the behaviour 
and his/her motivation 
to comply with these 
individuals/ groups 
The individual's 
evaluation of internal 
factors (ease or 
difficulty of 
performing the 
behaviour) and 
external factors 
(available resources 
and anticipated 
obstacles) 
Attitude 
towards the 
behaviour 
Subjective 
norms 
Perceived 
behavioural 
control 
Behaviour 
Figure 2. Components of the Theory of Planned Behaviour (Ajzen, 1988). 
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2.6.2 The TPB and WTP in an HIV vaccine trial 
A review of the literature revealed that there is a lack of theoretical work conducted around WTP in 
HIV vaccine trials. Moreover, there are no studies which have incorporated the TPB as a predictive model of 
WTP in an HIV vaccine trial. Although the intention to receive a future HIV vaccine is vastly unrelated to 
participation in an HIV vaccine trial, Gagnon and Godin (2000) evaluated the acceptability of a hyvothetical 
future HIV vaccine among adolescents using the TPB as a predictive modeL The results indicated that of the 
136 adolescents surveyed, 88% of the adolescents had a moderate to high intention to receive the HIV 
vaccine (Gagnon & Godin, 2000). Moreover, results of a multiple logistic regression analysis showed that 
two psychosocial variables from the TPB were significant predictors of the adolescents' intentions to receive 
the HIV vaccine. The two contributing factors were the adolescents' attitude toward receiving the HIV 
vaccine (OR = 4.80,95% C.L = 2.08-13.05) and the perceived behavioural control of receiving the HIV 
vaccine (OR = 2.52, 95% c.I. = 1.17-6.05) respectively. However, whether or not the TPB is predictive of 
WTP in an HIV vaccine trial among South African adolescents is uncertain and requires investigation. 
2.7 Application of the TPB in the present study 
The TPB has been used to assess a variety of behaviours including health-related behaviours such as 
testicular self-examination (e.g.: Brubaker & Wickersham, 1990), clinical glove use (e.g.: Watson & Myers, 
2001), treatment adherence in various populations (e.g.: Conner et a1., 1998; Poveyet a1., 2000), HIV 
preventative behaviours (e.g.: Albarracin et aL, 2001; Boer & Mashamba, 2005; Giles et aI., 2005; McCabe 
& Killackey, 2004) and intentions to receive various vaccinations (e.g.: de Wit et aI., 2004; Gagnon & Godin, 
2000). 
There is a lack of theoretical work conducted around WTP in HIV vaccine trials. It may therefore be 
usefl.ll to apply existing models of health behaviour to gain an understanding of WTP in an HIV vaccine trial. 
Kafaar et a1. (2006) address an important issue which arises from the application of a theory commonly used 
to understand health behaviours (such as the TPB) to HIV vaccine trial participation. Health behaviours are 
conventionally regarded as the maintenance of health and prevention of illness (Kasl & Cobb, 1966; Marks, 
Murray, Evans, & Willig, 2000; Matarazzo, 2002; Ogden, 2004). Moreover, health behaviours are 
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traditionally understood as acts from which individuals benefit directly. Participation in an HIV vaccine 
trial is regarded as a behaviour which may potentiaily contribute to changes in public health (by possibly 
contributing to the long term decline of HIV incidence). However, behaviours which contribute to changes in 
public health are not conventionally understood as health behaviours (Kafaar et aI., 2006). 
Therefore, from a traditional point of view, critics may question whether participation in an HIV 
vaccine trial can be regarded as a health behaviour as participation in an HIV vaccine trial poses no direct 
health benefits to the participants as such. Thus it is appropriate to question the extent to which a theory 
commonly used to understand health behaviours can be applied to behaviour such as HIV vaccine trial 
participation. Kafaar et al. (2006) argue that whether or not participation in an HIV vaccine trial can be 
regarded as a health behaviour depends on whether it is viewed from the individual's perspective or from the 
perspective of the researcher. 
From an individual perspective, pmiicipants may benefit from participation in an HIV vaccine trial. 
These individuals may perceive that receiving the HIV vaccine might offer increased protection from HIV 
above that of an individual who does not receive an HIV vaccine. Trial participation can be regarded as a 
health behaviour as anticipated protection from HIV infection may follow. Moreover, participation in an HIV 
vaccine trial and regular visits to trial site clinics reminds individuals repeatedly of their high risk for HIV 
infection (Kafaar et aI., 2006). In a recent study conducted by Lesch et al. (2006) respondents in fact 
reported that participation in an HIV vaccine trial would be a means to protect themselves from HIV 
infection. These factors may be seen as health-promoting behaviours. 
From the researcher's perspective however, health benefits to individual participants are not a 
primary concern. The primary aim of developing an effective HIV vaccine is to improve public health. 
Investigators are primarily concerned with designing ethically, legally and scientifically valid trials. In fact, 
investigators may consider it inappropriate to regard participation in an HIV vaccine trial as a health 
behaviour as none or not all the participants may directly benefit from HIV vaccine trial participation (Kafaar 
et ai., 2006). 
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Researchers investigating HIV vaccine trial participation may use traditional health promotion 
models such as the TPB and others due to an absence of tested theoretical models (Kafaar et aI., 2006). Given 
the uncertainty of the applicability of such models to research in this area, this presents researchers with the 
challenge of moving beyond the limited focus on such theories and engaging in a process of theory-testing 
and theory-building. This process of theory-testing and theory-building allows including and testing the 
suitability of existing theoretical models. It may also promote understanding of the multifaceted nature of 
HIV vaccine trial participation and the eventual development of robust theoretical models for explaining this 
construct. 
Due to the fact that WTP in an HIV vaccine trial is hypothetical in nature, no overt behaviour was 
tested using the TPB in the present study. The intention to participate in an HIV vaccine trial was regarded as 
synonymous to WTP in an HIV vaccine trial. As stated by Albarracin et a1. (2001) an individual's overt 
behaviour is determined by the individual's intention/or willingness to perfonn the specific behaviour. 
Previous research has therefore regarded the intention to perfonn a behaviour and willingness to perfonn a 
behaviour as synonymous constructs. For the purpose of the present study then, whether or not an individual 
will be willing to participate in an HIV vaccine trial is influenced by three detenninants, namely: an 
individual's positive or negative evaluations towards participation in an HIV vaccine trial, the perceived 
social pressure to participate or not participate in an HIV vaccine trial and lastly, the individual's self-
efficacy with respect to participation in an HIV vaccine trial, despite difficult circumstances (see Figure 3). 
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I The individual's 
beliefs that the Attitude 
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Figure 3. Use of the Theory of Planned Behaviour (Ajzen, 1988) in the present study. 
Stellenbosch University  http://scholar.sun.ac.za
3.1 Research design 
CHAPTER 3 
RESEARCH METHODOLOGY 
The present study was a research survey with a cross-sectional design. 
3.2 Participants 
A total of 224 grade 10 and 11 learners were selected by means of convenience sampling from two 
secondary schools located in an African township on the Cape Flats. 
3.3 Procedure 
27 
Permission to conduct research in the above schools was first obtained from The ~Western Cape 
Education Department and subsequently, ethical clearance and permission was obtained from the University 
of Stellenbosch' Internal Review Board. 
The researcher met with the school principals in order to make the necessary arrangements and gain 
pennission to conduct the relevant research. Subsequently, the researcher and a research assistant carried out 
the data collection. Groups of grade 10 and 11 learners were brought together in the school hall or classrooms 
where the researcher was introduced to them. The researcher carefully explained the study to the participants 
and subsequently, the participants were asked to sign an infonned consent fonn (see Appendix A). The 
researcher presented a short pre-test workshop in which the HIV vaccine and the HIV vaccine trial were 
explained to the participants. Participants then completed the battery of instruments. Once the data collection 
was complete, the participants were thanked for their time and received crisps and sweets in gratitude of their 
participation. 
3.4 Measuring instruments 
All questionnaires were administered in English and Xhosa. 
3.4.1 Demographic variables 
Gender, age, grade and ethnicity were assessed using a self-administered questionnaire (Appendix B). 
3.4.2 Perceived risk of HIV infection 
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To measure participants' self-perceived risk of HI V infection, a visual analogue scale was 
developed by the researcher (see Appendix B). A visual analogue scale (VAS) is an instrument which is used 
to measure constructs and attitudes or opinions about specific stimuli, which range across a continuum and 
cannot be directly or categorically measured easily. A VAS is usually a lOcm horizontal line and is anchored 
by descriptive words on each end of the line. The participants mark on the line the point they perceive to 
represent their current statc or feeling toward that which is being measured (Gould, Kelly, Goldstone, & 
Gammon, 2001). The participants were requested to indicate with a cross on the continuum ranging from 
"very low risk" (0 cm) to "very high risk" (12 cm), how much at risk they thought they were of contracting 
HIV. Higher scores indicated a higher perceived self risk of HIV infection. 
3.4.3 Willingness to participate (WTP) in an HIV vaccine trial 
To measure participants' WTP in an HIV vaccine trial, a visual analogue scale was developed by the 
researcher (see Appendix B). The participants were requested to indicate with a cross on the continuum 
ranging from "very unwilling to participate" (0 cm) to "very willing to pm1icipate" (12 cm), how willing they 
were to participate in a hypothetical Phase III HIV vaccine triaL Higher scores indicated a greater WTP in an 
HIV vaccine trial. 
3.4.4 Knowledge of HIV vaccines and HIV vaccine trials 
In order to measure participants' knowledge of HIV vaccines, HIV vaccine trials and related 
concepts, an instrument was developed by the researcher and members of the Socio-behavioural working 
group, SAA VI, Stellenbosch University (see Appendix C). The instrument consisted of23 items (with a two-
option response format consisting of "true" and "false"). Examples of items which appeared in the instrument 
are as follows: "a placebo is a fake treatment that is similar to the real vaccine or drug", "HIV vaccines are 
given to help prevent someone from becoming infected with HIV" and "if you enrol in an HIV vaccine trial 
you will get the appropriate medication, medical tests, and HIV tests regularly all the way through the trial." 
The instmment was scored by giving a 1 for a conect response and a 0 for an inconect response. Therefore, a 
minimum total score of 0 and a maximum total score of 23 was possible. Higher scores indicated an 
increased knowledge about HIV vaccines, HIV vaccine trials and related concepts. A panel of experts in the 
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Socio-behavioural working group, Si\A VI, Stellenbosch University reviewed the newly constructed 
instrument before it was used. Cronbach alpha reliability coefficients were subsequently calculated and are 
reported in the Results chapter. 
3.4.5 Attitude towards HIV/AIDS 
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To measure participants' attitude towards HIV/AIDS, the AIDS-related Stigma Scale 
developed by Kalichman et al. (2005) was used (see Appendix D). The scale consisted of nine items (with a 
two-option response format consisting of "I agree" and "I disagree"). However, for the present study, this 
two-option response format was changed to a four-option Likert response format ranging from "strongly 
disagree" to "strongly agree" in order to achieve continuity in pmiicipant responses. Positively worded items 
such as "it is safe for people with AIDS to work with children" were scored from 1 (strongly disagree) to 4 
(strongly agree). Negatively worded items such as "people who have AIDS are dirty" were reverse scored 
from 4 (strongly agree) to 1 (strongly disagree) in order to maintain the negative response set. Higher scores 
indicated a more positive participant attitude towards HIVI AIDS. In order to ensure that the scale not only 
measured AIDS stigma but also measured positive attitudes towards HIV/AIDS, item number 7 "people who 
have AIDS should be isolated" was changed to "people who have AIDS should not be isolated" and item 
number 9 "people who have AIDS should not be allowed to work" was changed to "people who have AIDS 
should be allowed to work". 
Research conducted in five South African communities found the scale to be internally consistent (a 
= 0.75), with alpha ranging from 0.64 and 0.83 across the samples. The sample consisted of 2306 participants 
who were 18 years and older. The scale was found to be stable over time, both at one month (r = 0.68, p < 
0.01) and three months (r = 0.67, p < 0.01). Moreover, the scale has internal consistency in English (alpha = 
0.78), Xhosa (alpha = 0.88) and Afrikaans (alpha = 0.71) (Kalichman et ai., 2005). Before the scale was used, 
the changes made were reviewed by a panel of experts in the Socio-behavioural working group, Si\A VI, 
Stellenbosch University. Subsequently, Cronbach alpha reliability coefficients were calculated for the 
adolescent sample and are reported in the Results section. 
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3.4.6 Health-promoting behaviours 
To measure pm1icipants' health-promoting behaviours, the Health-Promoting Lifestyle Profile 
(HPLP) developed by Walker, Sechrist, and Pender (1987) was used (see Appendix E). However, in order to 
avoid response fatigue, the original instrument consisting of 48 items was sh0l1ened into a 15 item instrument 
(with a four-point Likert-type format, consisting of four possible responses: "Never", "Sometimes", "Often" 
and "Routinely"). The instrument consisted of six sub-scales representing dimensions of a healthy lifestyle: 
Self-actualisation, Health responsibility, Exercise, Nutrition, Interpersonal support and Stress management 
(\Valker et a1., 1987). Participants were asked to indicate how frequently they performed each health-
promoting behaviour. ~When scoring the instrument, a total score and a score for each sub-scale was obtained. 
Higher scores indicated more frequent performance of the healthy lifestyle behaviours. The alpha reliability 
coefficients for each sub-scale reported by Walker et al. (1987) are as follows: Self-actualisation: 0.90; 
Health responsibility: 0.81; Exercise: 0.81; Nutrition: 0.76; Interpersonal support: 0.80 and Stress 
management: 0.70. The total instrument was found to have an alpha reliability coefficient of 0.92. 
FUl1hennore, to establish stability, the scale was administered twice at a two week interval period. The 
Pearson r was 0.93 for the total scale and ranged from 0.81 to 0.91 for the subscales (Walker et al., 1987). 
The 48 item instrument was shortened into a 15 item instrument using the factor loadings of each sub-scale 
reported by Walker et al. (1987). Items with the highest factor loading were selected for the short form of the 
instrument. These items and their corresponding factor loadings are sUlmnarised in Table 1. Before the 
instrument was used, the changes made were reviewed by a panel of experts in the Socio-behavioural 
working group, SAA VI, Stellenbosch University. Thereafter, Cronbach alpha reliability coefficients were 
calculated and are reported in the Results chapter. 
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Table 1 
Items and Factor Loadings of the Shortened Version of the Health-Promoting Lifestyle Profile (N= 15) 
Sub-scale and items 
Self-actualisation 
I feel content and at peace with myself 
I find each day interesting and challenging 
I believe that my life has purpose 
I like myself 
Health responsibility 
Factor 
loading 
0.72 
0.71 
0.71 
0.70 
I ask for infonnation from health professionals about how to take good care of myself 0.75 
I discuss my health concerns with health professionals 
I check my blood pressure 
Exercise 
I exercise vigorously for 20 minutes or more at least three times a week 
I do stretching exercises at least three times per week 
I eat three meals daily 
I eat breakfast 
Nutrition 
Interpersonal support 
I touch and am touched by people I care about 
I maintain meaningful and fulfilling relationships with others 
Stress management 
I relax my muscles before I sleep 
I use specific methods to control my stress 
0.69 
0.60 
0.82 
0.78 
0.85 
0.75 
0.69 
0.59 
0.54 
0.53 
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3.4.7 Attitude towards participation in an HIV vaccine trial 
Using questionnaire guidelines provided by Francis et aL (2004), a questionnaire with nine 
items was constructed by the researcher and members of the Socio-behavioural working group, SAA VI, 
Stellenbosch University (see Appendix F). The questionnaire consisted of a stem which defined the 
behaviour under investigation ("participating in an HIV vaccine trial is") followed by the use of evaluative 
bipolar adjectives such as "worthwhile/worthless" on a scale from 1 to 7. The scale was constructed so that 
the endpoints were a mix of positive and negative adjectives. Examples of items which appeared in the 
questionnaire are as follows: "participating in an HIV vaccine tlial is worthwhile/worthless", "participating 
in an HIV vaccine trial is harmfulibeneficial" and "paIiicipating in an HIV vaccine tlial is 
pleasant/unpleasant". When scoring the questionnaire, items with negative endpoints were reverse coded, so 
that higher scores reflected a more positive attitude toward participating in an HIV vaccine trial. 
Subsequently, the mean of the item scores was calculated to obtain an overall attitude score. A panel of 
experts in the Socio-behavioural working group, SA.i~VI, Stellenbosch University reviewed the newly 
constructed questionnaire before it was used. Internal consistency of the measure was subsequently analysed 
and alpha reliability coefficients are reported in the Results section. 
3.4.8 Subjective nornlS 
To measure subjective nonns, the researcher and members of the Socio-behavioural working 
group, SAA. VI, Stellenbosch University constructed a questionnaire with six items (see Appendix G) using 
questionnaires construction guideiines provided by Francis et al. (2004). The questionnaire used a four-point 
Likert scale response fonnat ranging from "strongly disagree" to "strongly agree". The questionnaire 
consisted of items such as: "most people who are important to me think that I should participate in an HIV 
vaccine trial", "it is expected of me to participate in an HIV vaccine trial" and "approval of my participation 
in an HIV vaccine trial is important to me". Items such as "most people who are important to me are willing 
to participate in an HIV vaccine tlial" were scored from 4 (strongly disagree) to 1 (strongly agree). Reverse 
scored items such as "I feel under social pressure to participate in an HIV vaccine trial" were scored from 1 
(strongly disagree) to 4 (strongly agree). Higher scores indicated a stronger perception of participation in an 
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HIV vaccine trial being the nonn. A panel of experts in the Socio-behavioural working group, SAA. VI, 
Stellenbosch University reviewed the newly constructed questionnaire before it was used. Internal 
consistency of the measure was subsequently analysed and alpha reliability coefficients are reported in the 
Results section. 
3.4.9 Perceived behavioural control 
Similar to above, questionnaire guidelines provided by Francis et al. (2004) were used to 
develop a scale which measured participants' perceived behavioural control (see Appendix H). This scale 
was constructed by a Psychology doctoral student at Stellenbosch University and members of the Socio-
behavioural working group, SAA VI, Stellenbosch University. The scale consisted of seven items with a four-
point Likert scale response fonnat ranging from "strongly disagree" to "strongly agree". The scale consisted 
of items such as: "I am confident that I could participate in an HIV vaccine trial ifI wanted to", "the decision 
to participate in an HIV vaccine trial is beyond my control" and "whether or not I decide to participate in an 
HIV vaccine trial is entirely up to me". Items such as "I am confident that I could participate in an HIV 
vaccine trial ifI wanted to" were scored from 1 (strongly disagree) to 4 (strongly agree). Reverse scored 
items such as "the decision to participate in an HIV vaccine trial is beyond my control" were scored from 4 
(strongly disagree) to 1 (strongly agree). Higher scores indicated a stronger perception of behavioural control 
over participation in an HIV vaccine trial. Before the scale was used, a panel of experts in the Socio-
behavioural working group, Stellenbosch University reviewed the newly constructed questionnaire. 
Thereafter, Cronbach alpha reliability coefficients were calculated and are reported in the Results section. 
3.5 Data analysis 
All statistical procedures were perfonned using the Statistical Package for the Social Sciences 
(SPSS) with an alpha level of 0.05. 
Deletion of cases with missing values was considered unsuitable because this would have reduced the sample 
size and in turn the statistical power of the study. Therefore, cases with missing values were included in all 
analyses. Firstly, frequencies (f), percentages (%), means (M), standard deviations (SD) and ranges were 
calculated for the independent variables. Secondly, the Kolmogorov-Smirnov (D) test of normality was 
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conducted in order to assess normality of the dependent and independent variable distributions. As a result 
of skewed distributions, the dependent variable was dichotomised in order to conduct logistic regression 
analyses on the data. Boxplots were requested to reveal the presence of outliers that could have exerted an 
unnecessary influence on the regression model. To test whether these outliers were significantly influential, 
standardised residuals were examined. Thereafter, Cook's distance was assessed. To test for any 
multicollinearity between predictor variables, the Variance Inflation Factor (VIF) statistic was assessed. 
Spearman's correlation coefficients were calculated to detennine the nature of any relationships between the 
independent variables and the dependent variable. Moreover, Speamlan's con'elation coefficients were 
calculated to determine the nature of any relationships between the demographic variables and the dependent 
variable. Finally, two multiple logistic regression analyses were performed. Firstly a hierarchical multiple 
logistic regression analysis was conducted, foilowed by a stepwise multiple logistic regression analysis. 
3.5.1 Predicting Willingness to participate in an HIV vaccine trial 
At step 1 in the first multiple logistic regression analysis, a hierarchical method was used in 
which Attitude towards participation in an HIV vaccine trial, Subjective norms and Perceived behavioural 
control were entered into the analysis to determine whether the TPB could significantly predict \VTP in an 
HIV vaccine triaL At step 2, the additional predictor variables of Perceived risk of HIV, KnO\vledge of HIV 
vaccines and HIV vaccine trials, Attitude towards HIV/AIDS and Health-promoting behaviours were added 
to Attitude towards participation in an HIV vaccine trial, Subjective norms and Perceived behavioural control 
to detennine whether these additional independent variables could further explain WTP in an HIV vaccine 
triaL 
Following the hierarchical logistic analysis, a second multiple logistic regression analysis was 
perfonned. This analysis was solely empirical and a forward stepwise likelihood ratio method was therefore 
used. The analysis involved one step in which Perceived risk of HIV, K.l1owledge of HIV vaccines, HIV 
vaccine trials and related concepts, Attitude towards HIV/AIDS, Health-promoting behaviours, Attitude 
towards participation in an HIV vaccine trial, Subjective norms and Perceived behavioural control were 
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entered simultaneously into the analysis to determine whether any of the above seven predictor variables 
could significantly predict WTP in an HIV vaccine trial. 
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CHAPTER 4 
RESULTS 
4.1 Demographic characteristics of the sample 
The sample consisted of 224 participants attending two secondary schools located in an African 
township on the Cape Flats. Of the 224 participants, 42.9% were 10th -grade learners and 56.7% were 11 th_ 
grade learners. The participants were, on average, 17 years of age (M = 17.3, SD = 1.5). Thc agc ofthc 
participants ranged from 14 to 21 years of age. All the participants were Black and there were more females 
(60.3%) than males (34.8%). These results are summarised in Table 2. 
Table 2 
Demographic Characteristics of the Sample 
N f (%) Nt SD Range 
School 224 (100) 
A 97 (43) 
B 127 (57) 
Grade 223 (99.6) 
10 96 (42.9) 
11 127 (56.7) 
Age (years) 222 (99.1 ) 17.3 1.5 14-21 
Race 224 (100) 
Black 224 (100) 
Sex 213 (95.1) 
:vlale 78 (34.8) 
Female 135 (60.3) 
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4.2 Data screening and tests of parametric assumptions 
The Kolmogorov-Smirnov (D) test of nonnality was used to assess the nonnality distributions of the 
dependent variable and independent variables (see Table 3). The results indicate that the dependent variable 
violated the assumption of nonnality, D(2IS) = 0.33, p < 0.01. The nonnality plot revealed a nonlinear 
relationship with distinct categories on the left and the right of the distribution and minimal cases falling in 
the middle of the distribution. As stated by Field (2000) modeling a non-linear relationship using a linear 
model limits the generalisability of the findings. Consequently, a decision was made to dichotomise the 
continuous dependent variable into those unwilling to participate in a future Phase III HIV vaccine trial and 
those willing to participate in a future Phase III HIV vaccine trial in order to conduct logistic regression 
analyses on the data. Participant scores for WTP in a future Phase III HIV vaccine trial ranged from Ocm 
to 12cm on the self-administered visual analogue scale. However, there were no participant scores ranging 
from 6-Scm for this variable. Subsequently, a decision was made to make the cut-off point at a score of Scm 
on the visual analogue scale. Therefore, WTP was dichotomised into the following categories: those 
unwilling to pmiicipate in a fJture Phase III HIV vaccine trial (a score below Scm) and those willing to 
participate in a future Phase III HIV vaccine trial (a score above Scm). The distributions of all the 
independent variables were significantly skewed (p < 0.05). However, in logistic regression, there are no 
assumptions about the nonnality of the predictor vaIiables and thus the predictors do not have to be nonnally 
distributed, linearly related or of equal variance (Tabachnick & Fidell, 2001). 
Boxplots were screened in order to identify any outliers in the dependent variable as well as the 
independent variables. The boxplots revealed the presence of outliers in the dependent variable as well as all 
the independent variables except Perceived risk of HIV infection and Attitude towards participation in an 
HIV vaccine trial. Consequently, Standardised residuals were examined in order to isolate cases for which 
the model fitted poorly and which could have influenced the regression model. According to Field (2000) 
Standardised residuals with an absolute value greater than 3 are cause for concern and indicate the presence 
of cases for which the model fits poorly and which could exert an undue influence on the regression model. 
Stellenbosch University  http://scholar.sun.ac.za
38 
Although the boxplots revealed the presence of outliers, the Standardised residuals did not exceed an 
absolute value greater than 2.S. Therefore, it was concluded that no cases were able to influence the 
regression model. Moreover, to consider the effects of a single case on the regression model as a whole, 
Cook's distance was examined. According to Field (2000) absolute values greater than one may be cause for 
concern and indicate that a single case may be influencing the model's predictive ability as a whole. 
Analyses of Cook's distance revealed no values above one. Therefore, it was concluded that no cases were 
able to unnecessarily influence the regression model. 
Lastly, correlations between predictor variables were examined to assess whether significant 
multicollinearity was present. The guidelines offered by Myers (1990) suggest that a Variance Inflation 
Factor (VIF) statistic exceeding 10 is a cause for concern. Analyses revealed that there were no VIF values 
exceeding lOin the data. Therefore, it was concluded that there was no significant multicollinearity between 
the predictor variables. 
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Table 3 
Normality Test/or Dependent Variable and Independent Variables 
Kolmogorov-Smirnov 
Variable Statistic df p 
Willingness to participate 0.33 215 0.00** 
Perceived risk of HIV 0.22 192 0.00** 
Knowledge of HIV vaccines 0.19 192 0.00** 
Attitude towards HIV/ AIDS 0.09 192 0.00** 
Health-promoting behaviour 0.07 192 0.00** 
Attitude towards participation 0.07 192 0.01 * 
Subjective nonns 0.16 192 0.00** 
Percei ved behavioural control 0.18 192 0.00** 
* p < 0.05 
** P < 0.01 
4.3 Internal consistency of measurement instruments used in the present study 
The guidelines offered by Nunaily (1978) suggest that an alpha reliability coefficient of 0.70 or 
higher is acceptable for scales used in beginning research. However, Reynaldo and Santos (1999) argue that 
lower thresholds have been deemed acceptable in existing literature. Guidelines offered by Huysamen 
(1996a, cited in Wolfaardt, 2001) suggest that an alpha reliability coefficient of 0.65 or higher is acceptable 
for decisions about groups. 
4.3.1 Knowledge of HI V vaccines and HIV vaccine trials 
The internal consistency analysis revealed a modest Cronbach alpha reliability coefficient (a = 0.65) 
for the measure. However, once the item "people who take part in HIV vaccine trials will receive free health 
care at the study clinic only for trial-related medical problems" was removed from the analysis, the internal 
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consistency improved (a = 0.77). The internal consistency could not be further improved. After the 
deletion of the above item, the final instrument consisted of 22 items. 
4.3.2 The AIDS-related Stigma Scale 
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The Internal consistency analysis of the AIDS-related Stigma Scale (Kalichman et aI., 2005) revealed 
a Cronbach alpha reliability coefficient of 0.49. Once the item "people with AIDS must expect some 
restrictions on their freedom" was removed from the analysis, the internal consistency improved (a = 0.59). 
Moreover, when the item "it is safe for people who have AIDS to work with children" was removed from the 
analysis, the internal consistency improved (a =0.60). The internal consistency could not be further 
improved. The instrument therefore consisted of seven items after deleting the above items. 
4.3.3 The Health-Promoting Lifestyle Profile 
The internal consistency analysis revealed an acceptable Cronbach alpha reliability coefficient for the 
measure (a = 0.70). The internal consistency could not be improved. 
4.3.4 Attitude towards participation in an HIV vaccine trial 
The internal consistency analysis revealed an acceptable Cronbach alpha coefficient for the measure 
(a = 0.75). It was therefore decided that this reliability coefficient did not require further improvement. 
4.3.5 Subjective nOlIDS 
The internal consistency analysis revealed a Cronbach alpha coefficient for the measure (a = 0.64). 
\Vhen the item "1 feel under social pressure to participate in an HIV vaccine trial" was removed from the 
analysis, the internal consistency improved (a = 0.75). The internal consistency could not be further 
improved. The total number of items remaining was five. 
4.3.6 Perceived behavioural control 
The internal consistency analysis revealed that the measure had modest internal consistency (a = 
0.52). Once the item "it would be very difficult for me to participate in an HIV vaccine tlial" was removed 
from the analysis, the internal consistency improved (a = 0.57). When the item "the decision to participate in 
an HIV vaccine trial is beyond my control" was removed, the internal consistency improved (a = 0.63). 
Finally, once the item "I would not be able to participate in an HIV vaccine trial even if I wanted to" was 
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removed from the analysis, the internal consistency improved (a =0.66). The internal consistency could 
not be further improved. The total number of items remaining was four. 
4.4 Analysis of demographic variables 
Spearman's correlation coefficients were calculated to determine the nature of any relationships 
between age and WTP, grade and WTP and gender and WTP in a future Phase III HIV vaccine trial. These 
results are summarised in Table 4. 
4.4.1 Age 
41 
No significant correlations were found between age and WTP in a future Phase III HIV vaccine trial 
(r = -0.05, p = 0.45). 
4.4.2 Grade 
No significant correlations were found between grade and \viP in a future Phase III HIV vaccine 
trial (r = -0.11, P = 0.12). 
4.4.3 Gender 
No significant correlations were found between gender and \VTP in a future Phase III HIV vaccine 
trial (r = 0.09, p = 0.19). 
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Table 4 
Spearman's Intercorrelations Between Demographic Variables and Willingness to Participate (WTP) in a 
future Phase III HIV Vaccine Trial (N = 202) 
WTP Age Grade Gender 
WTP 
Age -0.05 1 
Grade -0.11 0.29** 
Gender 0.09 -0.07 -0.03 
** p < 0.01 
4.5 Correlations between predictor vmiables and WTP 
Speannan's correlation coefficients were calculated to detem1ine the nature of any relationships 
between the predictor variables and \\liP in a future Phase III HIV vaccine trial. These results are 
summarised in Table 5. 
4.5.1 Perceived risk of HI V infection 
42 
No significant correlations were found between Perceived risk of HIV infection and WTP in a future 
Phase III HIV vaccine trial (r = -0.09, p = 0.22). 
4.5.2 Knowledge of HI V vaccines and HIV vaccine trials 
No significant correlations were found between Knowledge and WTP in a future Phase III HIV 
vaccine trial (1' = 0.05, P = 0.51). 
4.5.3 Attitude towards HIV/AIDS 
No significant correlations were found between Attitude towards HIViAIDS and WTP in a future 
Phase III HIV vaccine trial (r = 0.06, p = 0.41). 
4.5.4 Health-promoting behaviours 
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No significant correlations were found between Health-promoting behaviours and WTP in a future 
Phase III HIV vaccine trial (r = 0.09, P = 0.17). 
4.5.5 Subjective norms 
A significant positive correlation was found between Subjective norms and WTP in a future Phase III 
HIV vaccine trial (r = 0.24, P = 0.01). 
4.5.6 Attitude towards participation in an HIV vaccine trial 
There was a significant positive correlation between Attitude towards participation in an HIV vaccine 
trial and WTP in a future Phase III HIV vaccine trial (r = 0.14, p = 0.05). 
4.5.7 Perceived behavioural control 
There were no significant correlations found between Perceived behavioural control and WTP in a 
future Phase III HIV vaccine trial (r = 0.12, p = 0.11). 
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Table 5 
Spearman's lntercorrelations Between Predictor Variables and Willingness to Participate in an HIV Vaccine Trial (N =194) 
WTP 
Perceived 
Risk 
Knowledge 
Attitude 
towards HIV/AIDS 
Health-
promoting behaviours 
Subjective 
Norms 
Attitude towards 
participation in an 
HIV vaccine trial 
Perceived behavioural 
control 
** p < a.OJ 
* p < 0.05 
WTP Perceived 
Risk 
-0.09 
0.05 -0.23** 
0.06 -0.13 
0.09 -0.13 
0.24** 0.11 
0.14* -0.09 
0.12 0.01 
Knowledge Attitude Health- Subjective Attitude towards 
towards promoting norms participation in an 
HIV/AIDS behaviours HIV vaccine trial 
0.39** 
0.11 0.16* 
0.05 0.13 0.10 
0.35** 0.19** 0.06 o.e)7 
0.01 0.39** 0.11 0.28** 0.09 
44 
Perceived 
behavioural 
control 
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4.6 Predicting Willingness to Participate (WTP) in a future Phase III HIV vaccine trial 
4.6.1 Regression model 1 
45 
In the hierarchical multiple logistic regression analysis, Attitude towards participation in an HIV 
vaccine trial, Subjective nonns and Perceived behavioural control were entered together in the first step. In 
the second step, Perceived risk of HIV infection, Knowledge of HIV vaccines and HIV vaccine trials, 
Attitude towards HIV / AIDS and Health-promoting behaviours were added to Attitude towards participation 
in an HIV vaccine trial, Subjective nonns and Perceived behavioural control. At the first and the second step 
of the hierarchical multiple logistic regression analysis, the Hosmer and Lemeshow goodness-of-fit test was 
conducted. The Hosmer and Lemeshow test statistic was non-significant (p >0.05) for both step one and step 
two of the analysis. These findings suggest that the model was a good fit of the data. Moreover, two 
additional evaluative indices were assessed, namely, Cox and Sneli R2 and Nagelkerke R2. These indices can 
be treated as additional evaluative indices such as the overall model evaluation and goodness-of-fit test 
statistics (Peng, Lee, & Ingersol, 2002). Similar to the Hosmer and Lemeshow goodness-of-fit test, both Cox 
and Snell R2 and Nagelkerke R2 for both steps in the regression analysis were non-significant (p >0.05) 
suggesting that the model was a good fit of the data. The Hosmer and Lemeshow goodness-of-fit test, Cox 
and Snell R2 and Nagelkerke R2 for each step are summarised in Table 6. 
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Table 6 
Goodness-of-fit Test Statistics and R2 for the Hierarchical ivlultiple Logistic Regression Ana~vsis 
Test 2 R2 df X P 
Step 1 
Hosmer and Lemeshow goodness-of-fit 11.32 8 0.19 
Cox and Snell 0.07 
Nagelkerke 0.11 
Step2 
Hosmer and Lemeshow goodness-of-fit 13.36 8 0.10 
Cox and Snell 0.08 
Nagelkerke 0.12 
4.6.2 In the hierarchical multiple logistic regression analysis, Attitude towards participation in an 
HIV vaccine trial, Subjective norms and Perceived behavioural control were entered together in the first step. 
As can be seen in Table 7, the chi-square test of the full model with all three predictors against a constant-
only model indicated an increase in the amount of information explained by the model as a result ofthe 
inclusion of the above three predictors. Moreover, the model chj-square test statistic was statistically 
significant indicating that the inclusion of the above three predictors significantly improved the prediction of 
WTP in a future Phase III HIV vaccine trial. Prediction success was high with 79.9% of cases conectly 
classified using the above three predictors. Subjective norms significantly predicted WTP in a future Phase 
III HIV vaccine trial, X2(l, N = 194) = 8.52, p = 0.00. The odds ratio indicated that as the perception of 
participation in an HIV vaccine trial being the nonn increased by one unit of measurement on the Subjective 
norms scale, the odds of WTP in a future Phase III HIV vaccine trial also increased, but negligibly (OR = 
1.19, 95% c.I. = 1.06-1.34). Although the Wald statistic for Attitude towards participation in an HIV vaccine 
trial was significant, X2( 1, N = 194) = 3.74, p = 0.05, this finding is likely to have little practical utility. 
Stellenbosch University  http://scholar.sun.ac.za
47 
Attitude towards participation in a future Phase III HIV vaccine trial was associated with an odds ratio of 
1.32. However, the confidence interval for the odds ratio included 1 (95% c.r. = 0.99-1.73). Therefore, there 
was no significant relationship between Attitude towards participation in an HIV vaccine trial and \VTP in a 
future Phase III HIV vaccine trial in this sample. Lastly, Perceived behavioural control did not make a 
significant contribution to the prediction ofWTP in a future Phase III HIV vaccine trial (p> 0.05). Therefore, 
of the three variables from the TPB, only Subjective norms significantly predicted WTP in a future Phase III 
HIV vaccine trial. 
In the second step of the hierarchical multiple logistic regression analysis, Perceived lisk of HIV, 
Knowledge of HIV vaccines and HIV vaccine trials, Attitude towards HIV I AIDS and Health-promoting 
behaviours were added to the model in order to determine whether the addition of the above predictor 
variables could further explain WTP in a future Phase III HIV vaccine trial. As can be seen in Table 7, the 
chi-square test of the block with the additional four predictors included in the model was non-significant 
indicating that the additional predictors did not improve the prediction ofWTP in a future Phase III HIV 
vaccine trial. Moreover, prediction success showed that only an additional 0.5% of cases were classified after 
the inclusion of the additional four predictors, with a total of 80.4% of cases conectly classified by the 
model. Similar to the findings in the first step, of the seven predictors included in the second step, only 
Subjective norms significantly predicted WTP in a future Phase III HIV vaccine trial, x2(l, N = 194) = 8.65, 
p = 0.00 and was associated with an odds ratio of 1.19 (95% C.L = 1.06-1.35). This finding indicated that the 
odds of WTP in a future HIV vaccine trial increased as the perception of participation in a future HIV 
vaccine trial being the norm increased by one unit of measurement on the Subjective norms scale, but 
negligibly. 
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Table 7 
Summary of the Hierarchical lvfu ltip Ie Logistic Regression AnaZvsis for Variables Predicting Willingness to 
Participate OtTP) in afilture Phase III HIV Vaccine Trial (N = 194) 
Predictor 
variable 
Step 1 
Constant 
Attitude 
towards 
participation 
Subjective 
nonus 
Perceived 
behavioural 
control 
Step 2 
Constant 
Attitude 
towards 
participation 
Subjective 
nonus 
Perceived 
behavioural 
control 
Perceived risk 
of HI V 
~ SE~ 
-2.30 1.13 
0.28 0.14 
0.17 0.06 
0.02 0.07 
-2.51 1.75 
0.27 0.15 
0.18 0.06 
0.04 0.08 
-0.06 0.06 
Wald's e~ 
2 df p (Odds 
X Ratio) 
13.58 3 0.00** 
4.13 0.04* 
3.74 1 0.05* 1.32 
8.52 1 0.00** 1. 9 
0.09 0.76 1.02 
1.86 4 0.76 
2.07 1 0.15 
3.44 1 0.06 1.31 
8.65 1 0.00** 1.19 
0.22 1 0.64 l.04 
0.94 0.33 0.95 
95% 
Confidence 
Interval 
0.99-1.73 
1.06-1.34 
0.89-1.17 
0.99-1.75 
1.06-1.35 
0.89-1.20 
0.85-1.06 
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Predictor Wald's e~ 95% 
variable SE~ 2 df p (Odds Confidence X Ratio) Interval 
Knowledge of 
HIV vaccine 0,09 0.07 0.02 0.89 1.01 0.89-1.15 
trials 
Attitudes 
toward -0,04 0,06 0.43 0,51 0,96 0.86-1.08 
HIV/AIDS 
Health 
promoting 0.22 0.03 0.55 1 0.46 1.02 0.96-1.09 
behaviours 
** p < 0.05 
* p < 0.01 
4.6.3 Regression model 2 
As a result of the findings of the hierarchical multiple logistic regression analysis, a second multiple 
logistic regression analysis was conducted which did not involve theory testing, but which was entirely 
exploratory. Therefore, a stepwise method was deemed suitable for this analysis. In the forward likelihood 
ratio logistic regression analysis2, Perceived risk of HI V infection, Knowledge of HIV vaccines, and HIV 
vaccine trials, Attitude towards HIV/AIDS, Health-promoting behaviours, Attitude towards participation in 
an HIV vaccine trial, Subjective nonns and Perceived behavioural control were entered simultaneously into 
the analysis to detennine whether any of the above seven predictor variables could significantly predict WTP 
in a future Phase III HIV vaccine trial. In order to assess the goodness-of-fit of the model at each step of the 
analysis, the Hosmer and Lemeshow goodness-of-fit test was conducted. Moreover, two supplementary 
evaluative indices (Cox and Snell R2 and Nagelkerke R2) were assessed. Aithough Cox and Snell R2 for step 
one was significant (p = 0.05), the Hosmer and Lemeshow goodness-of-fit test statistic at both step one and 
step two was non-significant (p >0.05). Additionally, Nagelkerke R2 was non-significant (p >0.05) at step 
one and step two. These findings suggest that the model was a good fit of the data. The Hosmer and 
2 A backward likelihood ratio method was also conducted and revealed the same results as the forward iikelihood ratio method. 
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Lemeshow goodness-of-fit test statistic, Cox and Snell R2 and Nagelkerke R2 for each step of the stepwise 
logistic regression analysis are summatised in Table 8. 
Table 8 
Goodness-oj-fit Test Statistics and R2 Jor the Fonvard Stepwise A1ultiple Logistic Regression Analysis 
Test 2 R2 df X P 
Step 1 
Hosmer and Lemeshow goodness-of-fit 10.00 " 0.19 I
Cox and Snell 0.05* 
Nagelkerke 0.08 
Step2 
Hosmer and Lemeshow goodness-of-fit 12.89 8 0.12 
Cox and Snell 0.07 
Nagelkerke 0.11 
*p :oS 0.05 
4.6.4 Of the seven predictors entered simultaneously into the forward stepwise logistic regression 
analysis, Subjective nonns and Attitude towards participation in an HIV vaccine trial could significantly 
predict WTP in a future HIV vaccine trial. As can be seen in Table 9, in the first step of the analysis, 
Subjective nonns was the most significant predictor of \VTP in a future Phase III HIV vaccine trial, X2( 1, N = 
194) = 9.26, p = 0.00 and was therefore added to the model first. The chi-square test of the full model with 
the above predictor was statistically significant indicating that the inclusion of Subjective nOlms significantly 
improved the prediction of \VTP in a future HIV vaccine trial. Moreover, prediction success was high, with 
78.4% of cases correctly classified using Subjective norms as a predictor variable. 
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In the second step of the analysis, Attitude towards pmiicipation in an HIV vaccine trial was added 
to the model. As can be seen in Table 9, the chi-square test of the step with the additional predictor included 
in the model was statistically significant indicating that the additional predictor further explained WTP in a 
future Phase III HIV vaccine trial. Prediction success showed that an additional 2% of cases were classified 
after the inclusion of Attitude towards patiicipation in an HIV vaccine trial, with a total of 80.4% of cases 
correctly classified by the model. Moreover, the model which included the above two predictor variables was 
compared to the model if the predictor variables were removed. The change in the model was statistically 
significant, suggesting that the inclusion of Subjective nonns and Attitude towards participation in an HIV 
vaccine trial improved the predictive ability of the model. Subjective nonns significantly predicted WTP in a 
future Phase III HIV vaccine trial, X2(1, N = 194) = 9.81, p = 0.00. The odds ratio indicated that as the 
perception of participation in a future Phase III HIV vaccine trial being the nonn increased by one unit of 
measurement on the Subjective nonns scale, the odds of WTP in a future HIV vaccine trial also increased, 
but negligibly (OR = 1.19, 95% c.I. = 1.07-1.34). Attitude towards participation in an HIV vaccine trial 
significantly predicted WTP in a future HIV vaccine tlia1, X2(l, N = 194) = 3.88, p = 0.05. The odds ratio 
indicated that as Attitude towards participation in an HIV vaccine trial increased by one unit of measurement 
on the Attitude towards paliicipation in an HIV vaccine trial scale, the odds of VVTP in a future HIV vaccine 
trial also increased, but negligibly (OR = 1.32,95% c.I. = 1.00-1.74). 
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Table 9 
Summary of the Forward Stepwise iVfultiple Logistic Regression Analysis for Variables Predicting 
Willingness to Participate (FVTP) in afuture Phase III HIV Vaccine Trial (TIl = 194) 
Predictor variable 
Step 1 
Constant 
Subjective norms 
Step 2 
Overail model 
Constant 
Attitude towards 
participation in an HIV 
vaccine trial 
Subjective norms 
**p < 0.01 
*p ~ 0.05 
-0.84 
0.l7 
-2.15 
0.28 
0.18 
Wald's SE~ 2 
X 
9.51 
0.73 1.33 
0.06 9.23 
3.98 
13.49 
1.01 4.55 
0.14 3.88 
0.06 9.81 
ep df p (Odds Ratio) 
1 0.00** 1 
0.25 0.43 
1 0.00** 1.18 
0.05* 
2 0.00** 
0.03* 0.12 
0.05* 1.32 
1 0.00** 1.19 
9~O/, ),0 
Confidence 
Interval 
1.06-1.32 
1.00-1.74 
1.07-1.34 
52 
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CHAPTERS 
DISCUSSION AND CONCLUSION 
5.1 Predicting WTP in a future Phase III HIV vaccine trial 
53 
The first aim of the present study was to detennine whether the inclusion of the TPB could 
significantly predict \VTP in a future Phase III HIV vaccine trial among high risk adolescents in the Westem 
Cape. The TPB is a social cognitive model commonly used to assess a variety of behaviours including 
health-related behaviours. For example, the TPB has been used in studies assessing testicular self-
examination (e.g.: Brubaker & Wickersham, 1990), clinical glove use (e.g.: Watson & Myers, 2001), 
treatment adherence in various populations (e.g.: Conner et aI., 1998; Povey et a1., 2000), HIV preventative 
behaviours (e.g.: Albarracin et a1., 2001; Boer & Mashamba, 2005; Giles et al., 2005; McCabe & Killackey, 
2004) as well as intentions to receive various vaccinations (e.g.: de Wit et a1., 2004; Gagnon & Godin, 2000). 
In the present study, the inclusion of the TPB significantly improved the prediction of WTP in an 
HIV vaccine trial among adolescents in the Westem Cape, with a high prediction success of79.9% of cases 
correctly classified using the TPB as a theoretical model. Subjective nonns significantly predicted WTP in an 
HIV vaccine trial and was associated with an odds ratio of 1.19 (95% C.I. = 1.06-1.34). Attitude towards 
participation in an HIV vaccine trial was associated with an odds ratio of 1.32. This finding is likely to have 
little practical utility as the confidence interval included 1. Therefore, there was no significant association 
between Attitude towards participation in an HIV vaccine trial and WTP in an HIV vaccine trial in this 
adolescent sample. Lastly, Perceived behavioural control did not make a significant contribution to the 
prediction of WTP in an HIV vaccine trial. The inclusion of the combination of the TPB variables 
significantly improved the prediction of WTP in a future Phase III HIV vaccine trial among this adolescent 
sample. However, Attitude towards participation in an HIV vaccine triai and Perceived behavioural control 
were not significant predictor variables individually. 
The second aim of the present study was to detennine whether the inclusion of the additional 
predictor variables of Perceived risk of HIV infection, Knowledge of HIV vaccines and HIV vaccine trials, 
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Attitudes toward HIV I AIDS and Health-promoting behaviours could further explain \ViP in a future 
Phase III HIV vaccine trial among high risk adolescents in the Western Cape. Prediction success remained 
mostly unchanged, with merely an additional 0.5% of cases classified after the inclusion of the additional 
four predictor variables. A total of 80.4% of cases were correctly classified with the inclusion of the 
additional four predictor variables. Moreover, the chi-square test of the step was non-significant, suggesting 
that the additional predictor variables did not improve the prediction of WTP in an HIV vaccine trial. Similar 
to the first step. of the seven predictors included in the second step, only Subjective norms significantly 
predicted WTP in an HIV vaccine trial and was associated with an odds ratio of 1.19 (95% C.L = 1.06-1.35) 
respectively. In this regression analysis, a hierarchical entry method was employed as this method is deemed 
to be most suitable for theory testing (Field, 2000). Although only Subjective norms was a significant 
predictor of \VTP in an HIV vaccine trial, these findings are important and may inform future research. These 
findings suggest that psychosocial factors may influence adolescents' WTP in a future Phase III HIV vaccine 
trial. 
5.1.1 Subjective norms as a predictor variable ofWTP in a future Phase III HIV vaccine trial 
Adolescence is a developmental stage typically associated with emotional maturity, identity 
development, development of a value system, independence and establishment of mature love relationships 
and friendships (Meyer, 2004b). The psycho-social crisis for this developmental stage is that of group 
identity versus alienation (Meyer, 2004b). Forming a relationship with one's peer group is therefore a 
developmental task at this stage (Heaven, 1994). Adolescents are typically in the process of evaluating 
themselves and their own actions in the context of a peer group and are pre-occupied with gaining peer group 
acceptance in order to be popular, loved and respected by peers their own age, who are faced with the same 
pressures and challenges (Kaplan, 2000). As suggested by ~White (1999) peer groups are a source of 
socialization for adolescents, and for many, more time is spent with peers than with adult counterparts or 
parents. The most important way in which peers influence one another is by group fonnation. Group norms 
are established, determining how members should look, act and think (Shaffer, 1993). Peer groups typically 
personify cultural norms and values that are of the essence to an adolescent. l'v10reover, among these groups, 
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strict nonus exist and those who deviate from the nonn are faced with ridicule or rejection by fellow group 
members (Heaven, 1994). 
The peer group has consistently been regarded as a fundamental context for growth and independence 
and fonus the basis for long term social functioning (Poole, 1989). Peer groups are well established at the 
high school level and membership in a peer group involves commitment, loyalty, intimacy, solidarity and 
adherence to group norms (Berger, 2000). Berger (2000) suggests that the social pressure to conform to peer 
groups (in behaviour, dress and attitude) is usually considered a negative experience. As argued by Meyer 
(2004b), although individuals can feel continuously pressured to conform to the group, peer groups can be 
constructive and strengthen self-confidence in adolescents. Consistent with this argument, Heaven (1994) 
suggests that the peer group plays a crucial role in providing role models and setting boundaries for 
behaviour as the growing adolescent deals with physiological maturity and identity formation. Newman and 
Newman (1999) suggest that because adolescents are aware of a variety of behaviours, roles, morals and life 
styles, social modelling is particularly important for self-growih and identity fonuation. Social modelling 
typically refers to the process of adolescents learning from external sources such as fellow peers. Being a 
member in a peer group and engaging in social modelling is a vehicle by which independence and identity 
are attained (Heaven, 1994). 
Peer group norms and peer pressure have been shown to influence adolescent behaviour (e.g.: 
Sieving, Eisenerg, Pettingell, & Skay, 2006; Zwane & Mngadi, 2004). Due to the fact that adolescents spend 
more time with peers than adult counterparts, the way in which peers teach each other about sex and AIDS 
will subsequently affect the way these individuals will behave (\\ihite, 1999). Moreover, if an individual is a 
member of a group in which fellow peers are engaging in risky behaviours, that individual is most likely to 
be inclined to do the same (\\1hite, 1999). Given that acceptance in a peer group is a developmental task at 
adolescence, it is likely that if participation in an HIV vaccine trial is a perceived group norm, this perceived 
group nornl may influence adolescents' decisions about future Phase III HIV vaccine trial participation. This 
may be the case in the present study as results showed that as participation in an HIV vaccine trial being the 
norm increased, so did the adolescents' \VTP in a future Phase III HIV vaccine trial. Moreover, because the 
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present research study was conducted in the school environment where the adolescents were surrounded 
by their peers, the participants may have potentially been more stringent in conforming to group norms. 
However, as suggested by Swartz et a1. (2005) peer group influence may potentially affect participation in an 
HIV vaccine trial in unpredictable ways. As adolescents progress through time, beliefs concerning factors 
such as social good may change. Therefore, group nonns need to be positively influenced (Swartz et aI., 
2005). 
Although no research has tested the ability of the TPB to predict WTP in an HIV vaccine trial, there 
is some evidence that subjective norms may influence VviP in future HIV vaccine trials (Lesch et aI., 2006). 
Participants in the study conducted by Lesch et a1. (2006) reported that negative reactions from family and 
community members would act as an inhibitor to participation in a HIV vaccine trial. Conversely, 
participants reported that positive family and community reactions to participation in an HIV vaccine trial, 
and the presence of role models would act as enablers to participation in HIV vaccine trials (Lesch et aI., 
2006). Participants emphasised the role that family members have in the decision making process of whether 
or not to participate in a future HIV vaccine trial (Lesch et ai., 2006). Therefore, it is evident that an 
individual's perception of the social pressure put on him/her by salient individuals to participate or not 
participate in a future HIV vaccine trial may playa crucial role in detennining "\'TP in a future Phase III HIV 
vaccine trial. 
5.2 Predicting \VTP in a future Phase III HIV vaccine trial (model 2) 
Given the null findings of Attitude towards paliicipation in an HIV vaccine trial and Perceived 
behavioural control as individual predictor variables, all seven predictors included in the present study were 
entered simultaneously into the model in the second logistic regression analysis. Therefore, none of the 
predictor variables were held constant in this analysis. Of the seven predictor variables entered 
simultaneously into the regression analysis, Subjective norms and Attitude towards participation in an HIV 
vaccine trial significantly predicted \VTP in an HIV vaccine trial. Subjective norms significantly improved 
the prediction of WTP in an HIV vaccine trial. Prediction success was high, with 78.4% of cases con-ectly 
classified using Subjective norms as a predictor variable. Moreover, Subjective nonns was associated with an 
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odds ratio of 1.19 (95% C.L = 1.07-1.34) respectively. When Attitude towards participation in an HIV 
vaccine trial was added to the model, the chi-square test of the step with the additional predictor included in 
the model was statistically significant indicating that Attitude towards participation in an HIV vaccine trial 
further improved the prediction of WTP in an HIV vaccine triaL Prediction success improved, with an 
additional 2% of cases correctly classified after the inclusion of Attitude towards participation in an HIV 
vaccine trial. A total of 80.4% of cases were cOITectly classified by the above two predictor variables. 
Attitude towards participation in an HIV vaccine trial was associated with a negligible odds ratio of 1.32 
(95% C.L = 1.00-1.74) respectively. None of the remaining five predictor variables significantly predicted 
WTP in a future Phase III HIV vaccine triaL 
In contrast to the first regression model which involved theory testing, this analysis was an entirely 
exploratory approach to predicting WTP in a future Phase III HIV vaccine trial. Consequently, a stepwise 
method was employed. This method is deemed suitable in situations in which no previous research exists on 
which to base hypotheses for testing (Field, 2000). Although the TPB has been used to assess a variety of 
health-related behaviours, there is a paucity of research which has incorporated the TPB as a predictive 
model of \VTP in an HIV vaccine triaL 
Demonstrating the robustness of regression analyses, the two psychosocial variables constituting the 
Theory of Reasoned Action (Attitude towards participation in an HIV vaccine trial and Subjective norms 
regarding participation in an HIV vaccine trial) proved to be significant predictors of WTP in a future Phase 
III HIV vaccine trial among adolescents in the Western Cape. Therefore, when none of the variables were 
held constant, the individual predictive ability of the above two predictors was strengthened. This suggests 
that psychosocial factors may playa crucial role in predicting \\iTP in a future Phase III HIV vaccine trial 
among adolescents. From the present study it is evident that isolating a theory such as the TPB may limit the 
prediction of WTP in an HIV vaccine trial. Instead, variables constituting an existing theory should be added 
to other variables, and these variables should be exposed to exploratory analyses. This process may initiate 
theory-testing and theory-building, as well as the eventual development of a robust theoretical model to 
explain the multifaceted nature of WTP in an HIV vaccine trial. 
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Although there is no research that has tested the ability of the TPB to predict WTP in a future HIV 
vaccine trial, the findings that Attitude towards participation in an HIV vaccine trial is predictive of WTP in a 
future HIV vaccine trial is somewhat analogous to the findings of Gagnon & Godin (2000) and Zimet et a1. 
(1999). Although this research focused on adolescents' intentions to receive a future HIV vaccine, which is 
vastly unrelated to HIV vaccine ttial participation, the findings nevertheless suggest that attitude towards the 
HIV vaccine significantly predicted adolescents' intention to receive a future HIV vaccine. Similarly, the 
results of the present study indicate that Attitude towards pat1icipation in an HIV vaccine trial was a 
significant predictor of vVTP in a future Phase III HIV vaccine trial. This finding may inform future research 
and suggests that positive attitudes toward participation in an HIV vaccine trial should be promoted among 
adolescents. 
5.4 Perceived behavioural control as a predictor of WTP in a future Phase III HIV vaccine trial 
The findings of the present study showed that Perceived behavioural control did not significantly 
predict \VTP in a future Phase III HIV vaccine tIial among adolescents in the Western Cape. As discussed by 
Ajzen (1988) perceived behavioural control is not entirely realistic in some situations, namely, if an 
individual has little infonnation about the behaviour in question, when available resources have changed, or 
when new and unfamiliar factors have entered into the situation. Therefore, assessing perceived behavioural 
control in these situations may limit the accuracy of behavioural prediction (Ajzen, 1988). 
Perceived behavioural control is influenced by an individual's control beliefs, namely, the beliefs 
about resources and opportunities available to perfonn the target behaviour. These beliefs may be based on 
past experience with the behaviour. Moreover, these beliefs will usually be influenced by information from 
extemal sources regarding the behaviour, by observing the experiences of salient others regarding the 
behaviour and by other factors that increase or decrease the perceived difficulty of performing the target 
behaviour (Ajzen, 1988). As suggested by Ajzen (1988) the TPB is a model in which the TRA is a special 
case. The TPB explicitly recognises that behaviours may not be under the complete volitional control of an 
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individual. However, when issues of control are not a fundamental consideration for an individual; the 
TPB reduces to the TRA (Ajzen, 1988). In cases where issues of control are not a fundamental consideration 
for an individual, neither intention nor actions will be influenced by beliefs of control over a specific 
behaviour, leaving attitudes toward the behaviour and subjective norms concerning the behaviour as the 
detenninants of interest (Ajzen, 1988). 
The findings of the present study, namely that Subjective norms and Attitude towards participation in 
an HIV vaccine trial were significant predictors of WTP in an HIV vaccine tJial among this adolescent 
sample in the Western Cape provides support for the Theory of Reasoned Action (TRA) in predicting 
adolescent enrolment in HIV vaccine tIials. Therefore, in this sample of adolescents, perceived behavioural 
control over participation in a future HIV vaccine trial was not a significant predictor. Instead, whether or not 
these adolescents would be willing to participate in a future Phase III HIV vaccine trial was influenced solely 
by their behavioural beliefs and nonnative beliefs. 
A possible explanation for the suppOli of the TRA and not the TPB as originally hypothesised is that 
in instances where beliefs about control over the behaviour are not primary to an individual, measuring 
perceived behavioural control may not be realistic and may limit the accuracy of behavioural prediction 
(Ajzen, 1988). Firstly, given that the present study was not aimed at recruiting participants for an HIV 
vaccine trial, it was clearly stipulated to the participants that the present study was merely assessing 
hypothetical WTP in a future Phase III HIV vaccine trial. Considering that hypothetical WTP in an HIV 
vaccine trial does not necessarily translate into actual WTP in an HIV vaccine trial (Buchbinder et al., 2004), 
issues of control over participation in a future HIV vaccine trial may not be among these adolescents' 
primary concerns. Preparations for future Phase III HIV vaccine trials are relatively new in developing 
countries such as South Africa. Moreover, research has shown that South Africans have low levels of 
knowledge regarding the HIV vaccine and HIV vaccine trials (Smit et at, 2006). South African communities 
have emphasised the need for information regarding HIV vaccines and HIV vaccine trials before being able 
to answer questions relating to WTP in these trials (Smit et a1., 2006). This lack of infonnation and 
unfamiliarity with the HIV vaccine trial may influence whether or not these individuals perceive issues of 
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control to be a fundamental consideration. Ajzen (1988) argues that an individual's control beliefs 
regarding the target behaviour are based on past experience with the behaviour, will usually be influenced by 
infonnation from external sources and by observing the experiences of salient others regarding the behaviour. 
Once again, considering the unfamilimity of South Africans with the HIV vaccine trial and the fact that 
Phase III HIV vaccine trials have not commenced in the country, these individuals have no reliable sources, 
information or experiences on which to base these control beliefs. Lastly, given that the majority of 
adolescents are still dependent on adult counterparts, these individuals are more likely to be concerned with 
attitudes and subjective norms regarding a hypothetical future Phase III HIV vaccine trial. As suggested by 
Swartz et aL (2005), there are constraints on the power and autonomy possessed by adolescents. The freedom 
to be in control of the behaviour in question is not likely to be determined by an adolescent but by those 
counterparts who they are dependent upon. 
5.5 Self-perceived risk of HIV infection as a predictor of WTP in a future Phase III HIV vaccine trial 
Much evidence suggests that there is a significant relationship between perceived risk of HIV 
infection and WTP in an HIV vaccine trial among numerous samples internationally, e.g. among Thai men 
(Jenkins et aI., 2000), gay and bisexual men in Canada (O'Connell et aI., 2002), men who have sex with men 
in Brazil (Perisse et aI., 2000), Indian samples (Sahay et aI., 2005) and Italian samples (Starace et aI., 2006). 
Although numerous studies have consistently reported a significant relationship between perceived 
HIV risk and WTP in an HIV vaccine trial in specific samples, there is a paucity of research focusing on this 
relationship among South African adolescents. Smit et al. (2006) found that in a South African sample 
consisting of 16-40 year old participants, self-perceived HIV risk was significantly associated with WTP in 
an HIV vaccine trial. Contrary to the findings of Smit et al. (2006), self-perceived risk of HIV infection was 
not a significant predictor of WTP in a future Phase III HIV vaccine trial among adolescent participants in 
the present study. However, the sample used in the study by Smit et al. (2006) was relatively small and 
consisted of participants who had already volunteered to be part of a longitudinal HIV -related study. 
Therefore, the finding that self-perceived risk of HIV infection was significantly associated with WTP in an 
HIV vaccine trial may not be generalisab!e to the entire community_ The results of the present study indicate 
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that among adolescents in the Western Cape, self-perceived susceptibility to HIV infection may not 
influence their decision to participate in a future Phase III HN vaccine trial. The relationship between 
perceived HIV risk and WTP in future HIV vaccine trials requires further investigation among South African 
communities. 
5.6 Knowledge of HIV vaccines and HIV vaccine trials as a predictor of vVTP in a future Phase III HIV 
vaccine trial 
Although prior research has provided evidence for a significant relationship between knowledge of 
HIV vaccines and \VTP in an HIV vaccine trial (Kiwanuka et aI., 2004; Koblin et aI., 2000; Sahay et aI., 
2005; Smit et aI., 2006; Starace et aI., 2006), Knowledge of HI V vaccines and HIV vaccine trials did not 
significantly predict \VTP in a future Phase III HIV vaccine trial among adolescents in the present study. The 
finding that Knowledge of HIV vaccines and HIV vaccine trials is not predictive of WTP in future Phase III 
HIV vaccine trials is congruent with those of Halpern et al. (2001) and Priddy et al. (2006). Although logistic 
regression has no assumptions about the normality of predictor variables (Tabachnick & Fidell, 2001), the 
distribution of knowledge scores were significantly negatively skewed, indicating a pile up of scores on the 
right of the distribution. This is known as a ceiling effect and indicates that the majority of the participants 
scored high on the knowledge questionnaire. Consequently, there was limited variance in knowledge scores 
and this may have resulted in poor external validity which may have contributed to the null findings. 
Contrary to the evidence that South African's have low knowledge of HI V vaccines and limited scientific 
literacy to understand HIV vaccine trial methodology (Smit et aI., 2006), the participants in the present study 
presented with high knowledge scores. 
Before paI1icipants completed the battery of instruments, a short pre-test workshop was presented in 
which the HIV vaccine and the HIV vaccine trial methodology was presented and explained to participants. 
Consequently, the high knowledge levels in this sample may be an indication of participants' recall of the 
infonnation presented to them regarding the HIV vaccine and HIV vaccine trial, rather than a true indication 
of knowledge levels in this sample. Moreover, contextual limitations associated with the data collection may 
have, in pmi, contributed to the high knowledge scores. Firstly, there were limited classroom facilities (lack 
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of space) and as a result, some participants were seated next to each other at the desks. Secondly, the 
teacher supervising the class read the questionnaires out to the participants in order to ensure that all 
participants finished in time for the next class scheduled to begin in that room. Given that the questionnaire 
assessing knowledge consisted of a true and false response option format, and that the teacher was reading to 
the participants, the adolescents may have regarded the process as a test or examination in which they were 
expected to give the coneet answer to the questions being asked. Participants may have been influenced by 
their teacher and their peers to give the conect answer and may have easily copied fellow peers seated at the 
same desk as them. 
5.7 Attitudes toward HIV/AIDS as a predictor ofWTP in a future Phase III HIV vaccine trial 
Although no prior research has directly focused on the relationship between attitudes toward 
HIV/AIDS and VviP in an HIV vaccine trial, in a qualitative research project conducted in South Africa, 
participants reported that the HIV vaccine's association with HIV/AIDS may be a potential inhibitor to 
participation in an HIV vaccine trial (Lesch et aI., 2006). Participants in the study by Lesch et al. (2006) 
reported that there is a pervasive generalised negative perception of HIV / AIDS in the community. In the 
present study, no significant relationship was found between Attitudes toward HIV/AIDS and WTP in a 
future HIV vaccine trial among adolescents in the \Vestern Cape. A possible reason for this null finding is 
that the AIDS-related Stigma Scale (Kalichman et al., 2005) used in the present study was not reliable in the 
adolescent sample. The guidelines offered by Nunally (1978) suggest that a reliability of 0.70 or higher is 
acceptable for scales used in beginning research. However, guidelines offered by Huysamen (l996a, cited in 
Wolfaardt, 2001) suggest that a reliability coefficient of 0.65 or higher is acceptable for decisions about 
groups. 
The Internal consistency analysis of the AIDS-related Stigma Scale (Kalichman et al., 2005) 
revealed a Cronbach alpha reliability of a = 0.49. After deleting two items, the internal consistency improved 
(a =0 .60). However, the internal consistency could not be fmiher improved. Following the guidelines 
provided by Huysamen (1996a, cited in Wolfaardt, 2001), the Cronbach alpha of a =0 .60 for the AIDS-
related Stigma Scale in the present study is not acceptable. Therefore, in the present study, the scale was not 
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the null findings. 
5.8 Health-promoting behaviours as a predictor ofWTP in a future Phase III HIV vaccine trial 
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No prior research has investigated the relationship between health-promoting behaviours and vVTP in 
an HIV vaccine trial. The findings of the present study showed no significant relationship between health-
promoting behaviours and vVTP in a future Phase III HIV vaccine trial among adolescents in the Western 
Cape. Health-promoting behaviours may not influence adolescents' decision to participate in a future HIV 
vaccine trial. A possible reason for this lack of association may be that the shortened fonn of the Health-
Promoting Lifestyle Profile (HPLP) (Walker et aI., 1987) used in the present study assessed solely health-
promoting behaviours. Although unrelated to vaccine trial participation, Zimet et a1. (1999) found that 
increased engagement in health-compromising behaviours (such as the use of marijuana and minimal 
condom use) was significantly associated with greater HIV vaccine acceptance among adolescents. It may be 
useful to measure a combination of health-promoting as well as health-risk behaviours. Given the lack of 
plior research, the relationship between health-promoting behaviours and WTP in an HIV vaccine trial 
requires further investigation. 
5.9 Demographic characteristics 
5.9.1 Age 
It has been reported that younger age is significantly associated with WTP in an HIV vaccine trial 
(Buchbinder et aI., 2004; Jenkins et ai., 1998; O'Connell et ai., 2002). Some evidence also suggests that 
increasing age is significantly associated with WTP in an HIV vaccine trial (Bartholow et aI., 1997; KobEn et 
ai., 1997; Smit et aI., 2006). The results of the present study indicate that age is not associated with \VTP in a 
future Phase III HIV vaccine trial. This finding is congruent with those of Jenkins et a1. (2000), Kiwanuka et 
ai. (2004), McGrath et a1. (2001) and Viera De Souza et a1. (2003). The null finding suggests that age may 
not influence the decision to participate in an HIV vaccine trial among this adolescents sample. Given that 
the sample used in the present study was an adolescent cohort, age is not likely to be a significant predictor of 
\\lIP in an HN vaccine trial. 
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5.9.2 Gender 
Previous studies have found males to be more willing to participate in an HIV vaccine trial (Jenkins et 
aL, 1998; Smit et al., 2006). The results of the present study indicate no gender differences in terms of WTP 
in a future Phase III HIV vaccine trial. This finding is congruent with those of Kiwanuka et aL (2004) and 
Sahay et al. (2005). The findings of the present study therefore indicate no gender differences in adolescents' 
\VTP in a future Phase III HIV vaccine trial. The null finding may, in part, be a result of low numbers of 
male participants relative to female participants. 
5.9.3 Education 
While some evidence suggests that high levels of education is significantly associated with WTP in 
an HIV vaccine trial (Jenkins et al., 2000), other studies have found that low levels of education is 
significantly associated with WTP in an HIV vaccine trial (Bartholow et aL, 1997; Perisse et al., 2000; Viera 
De Souza et al., 2003). The results of the present study indicate that education was not associated with 
adolescents' WTP in an HIV vaccine trial. This finding is congruent with that of Kiwanuka et al. (2004). 
Education may not influence adolescents' decision to participate in an HIV vaccine trial. 
5.9.4 Race 
There is evidence that race is significantly associated with WTP in an HIV vaccine trial (Bartholow et 
aI., 1997; Buchbinder et al., 2004; Halpern et al., 2001). Congruent with the findings of Viera De Souza et 
al., 2003, the results of the present study showed no significant relationship between race and WTP in a 
future Phase III HIV vaccine trial. However, the sample used in the present study was homogenous. 
Therefore the lack of racial differences contributed to the null findings. 
5.10 Implications and social relevance 
The findings of the present study suggest that psychosocial detelminants may influence adolescents' 
decision to enrol in a future Phase III HIV vaccine trial. HIV vaccine preparedness programs targeting 
adolescents should aim to influence group nonns positively, increase normative pressure and motivate 
adolescents to comply with this nonnative pressure to participate in an HIV vaccine triaL Additionally, HIV 
vaccine preparedness programs should aim to promote positive attitudes toward participation in a future 
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Phase III HIV vaccine trial among adolescents. Positive group nonns and positive attitudes toward 
participation in an HIV vaccine trial may promote participation in a future Phase III HIV vaccine trial among 
young adults. Consequently, pmiicipation in an HIV vaccine trial may contribute to changes in public health 
and the eventual development of a safe and effective HIV vaccine to control the HIV pandemic. 
5.11 Limitations 
There were contextual difficulties associated with the data collected in this sample of adolescents. 
The lack of space and time resulted in a few participants being seated around one desk. Moreover, the 
questionnaires were read to the participants by the supervising teacher in order to ensure that participants 
finished in time for the next scheduled class in the room. These two contextual constraints may have led to a 
lack of variability in participant scores, specifically for the knowledge questionnaire. Participants may have 
been influenced by their fellow peers and social desirability responding may have been introduced. As a 
result of peer influence as well as the fact that the teacher read questionnaires to the participants, participants 
may have regarded the process as a test or examination in which they were expected to give the correct 
answer to the questions being read out to them. Therefore, it is a possibility that the participants may have 
influenced each other's responses. These contextual constraints may have resulted in poor external validity. 
Therefore, the extent to which the results of the present study can be generalised to the entire adolescent 
population is uncertain. 
5.12 Directions for future research 
Future research should consider implementing further quantitative research among South African 
adolescents in order to identify salient factors that may affect WTP in a future Phase III HIV vaccine trial. 
There is a paucity of research focusing on adolescents' \VTP in future HIV vaccine trials, both internationally 
and in the South African context. Significant predictors of participation in a future HIV vaccine trial among 
adult samples may not be as salient for South African adolescents. Incorporating significant predictors that 
have been investigated in prior research studies, as well as those which have not yet been tested may initiate 
the process of theory-building. Future research aimed at determining the multifaceted nature of participation 
in a future Phase III HIV vaccine among South African adolescents awaits further investigation. 
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Department of Psychology 
(021) 808 3461 
CONSENT TO PARTICIPATE IN RESEARCH 
77 
IDENTIFICATION OF FACTORS AFFECTING \VILLINGNESS TO PARTICIPATE IN AN HIV 
VACCINE TRIAL 
INVITATION TO PARTICIPATE 
You are cordially invited to take part in the aforementioned research project. 
AIM 
The aim of this research project is to establish the factors that could affect individuals' willingness to 
participate in future HIV vaccine trials. 
PROCEDURE 
As a participant, you will be part of the study and asked to complete a questionnaire packet measuring 
various factors that may influence willingness to participate in an HIV vaccine trial (such as knowledge of 
HIV vaccines and vaccine trials, health lifestyJe patterns and attitudes toward HIV/AIDS and HIV vaccines). 
POTENTIAL COSTS, RISKS AND DISCOMFORT 
There is no financial cost, risk or discomfort directly associated with taking part in this project. 
POTENTIAL BENEFITS TO SUBJECTS ANDIOR SOCIETY 
There is no guarantee that you will benefit directly from the study but your participation will contribute to the 
research in this field and therefore eventually be a benefit to society if a safe and effective vaccine is 
developed to prevent HIV. 
COMPENSA TION 
By agreeing to take part in this research study, you will receive a small token of appreciation for your 
participation. 
CONFIDENTIALITY 
Every attempt will be made to keep all information collected in this study strictly confidential, except as may 
be required by court order or by law. If any publication results from this research, you will not be identified 
by name. 
ADDITIONAL INFORMATION 
Your participation in this study is completely voluntary, and you are free to refuse to take part. You may 
stop taking part at any time without consequences of any kind. If you stop taking part in the project, you may 
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ask that we not use the infonnation already given to us. You may also refuse to answer any questions you 
don't want to answer and still remain in the study. The investigator may withdraw you from this research if 
circumstances arise which warrant doing so. You are encouraged to ask questions about the study at any time 
as they occur to you during the programme. Any important new findings developed during the course of the 
study that may relate to your willingness to continue taking part will be given to you. 
DISCLAIMER! WITHDRAWAL 
You agree that taking part in this study is completely voluntary and that you may stop at any time. 
SUBJECT RIGHTS 
If you have any questions regarding taking part in this research study, you may contact the Principal 
Investigator, Georgina Giocos, by teiephoning 082 778 73 78 or the Research Supervisor, Professor Ashraf 
Kagee, by telephoning (021) 808 3442. 
CONCLUSION 
By signing below you are indicating that you have read and understood the consent form and that you agree 
to take part in this research study. 
Subject's signature Date 
Investigators signature Date 
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IDYUNIVESITHI Y ASE STELLENBOSCH 
Isebe leSayikholoji (uBunzululwazi ngengqondo) 
(021) 8083461 
IMVUME YOKUTHATHA INXAXHEBA KUPHANDO 
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UK\VAZISWA KWEMIBA ENXULUMENE NOKUBA NOMDLA EKUTHATHENI INXAXHEBA 
KUV AVANYO/UKULINGWA K\VEYEZA ELIKHUSELA UMNTU At~GOSULEL'VA YIHIV 
ISIMEMO SOKUTHA THA INXAXHEBA 
Uyamenywa ngobubele ukuba uthathe inxaxheba kule nkqubo yophando ekhankanY\ve apha ngasentla. 
INJONGO 
Injongo yolu phando kukufumanisa ngemiba enokuthi inxulumane nomdla wabantu ekuthatheni inxaxheba 
kuvavanyo lukulingwa kweyeza elikhusela ukungosulelwa yiHIV kwixesha elizayo. 
IMIGAQO 
Njengothatha inxaxheba, uza kuba yinxalenye yale nkqubo kwaye uzakucelwa ukuba ugcwalise umquiu 
wephepha lemibuzo elivavanya iintlobo ngeentlobo zemiba enokuchaphazela umdla ekuthatheni inxaxheba 
kuvavanyo lukulingwa kweyeza elikhusela ukungosulelwa yiHIV (njengolwazi lwamayeza akhusela 
ukungosuleleki yiHIV,kunye nokuvavan)"vva kwamayeza akhuselayo, iindlela zokuphiia kunye nezimvo 
ngamayeza akhusela ukungosulelwa yiHIV/AIDS). 
IINTLA WULO, UBUNGOZI KUNYE NOKUNGAKHULULEKI OKUNOKUBAKHO 
Akusayibaki~o zintlavvulo, bungozi okanye ukungaki~ululeki okuqondene ngqo nokuthatha inxaxheka kule 
nkqubo. 
INZUZO KUBATHATHI NXAXHEBA KUNYE/OKANYE KULUNTU. 
Akukho siqinisekiso sokuba kungakho inzuzo eqondene ngqo nale nkqubo kodwa ukuthatha kwakho 
inxaxheba kuza kuba negalelo kuphando ngalo mxholo ze ekugqibeleni kube luncedo kuluntu xa iyeza 
elikhuselekileyo nelisebenza ngokufanelekileyo lifunyaniswe ukuba linqada ukosuleleka yiHIV. 
ISIBONELELO 
Ngokuthatha inxaxheba kule nkqubo yophando , uza kufumana isibonelelo esingephi njengombulelo 
wokuthatha kwakho inxaxheba. 
IMFIHLELO 
Inzame yokuba ulwazi oluqokelelweyo luhlale luyimfihlelo kule nkqubo luzakwenziwa, ngaphandle kwaxa 
lunokufunwa yinkundla okanye ngokwasemthethweni. Xa kungakho upapasho olwenziwayo kolu phando, 
igama lakho alisayi kukhankanywa. 
UL\VAZIOLWENGEZELELWEYO 
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Ukuthatha inxaxheba kolu phando lolokuzinikela ngokupheleleyo, kwaye ukhululekile ukwala ukuthatha 
inxaxheba. Unganqumama ekuthatheni inxaxheba nanini na ngaphandle kokusengelwa phantsi. Xa uyeka 
ukuthatha inxaxheba kule nkqubo yophando, unakho ukucela ukuba singalusebenzisi ulwazi osinike lona. 
Kwakhona unakho ukwala ukuphendula nayiphi na imibuzo ongafuni kuyiphendula kwaye uhlale ukule 
nkqubo. Umphandi angakuyekisa kolu phando xa iimeko zinyanzelisa. Uyakhuthazwa uba ubuze imibuzo 
ebhekiselelele kolu phando nanini na ngendlela evela ngayo kuwe ngexesha lale nkqubo. 
UKUYEKA 
80 
Uyavuma ukuba uk'Uthatha inxaxheba kolu phando lolokuzinikela ngokupheleleyo yaye ungayeka nanini na. 
AMALUNGELO ALO"VO UTHATHA INXAXHEBA 
Xa unemibuzo malunga nokuthatha inxaxheba kule nkqubo yophando, ungatsalela Umphathi Omkhulu 
wophando, uGeorgina Giocos, ngokutsalela Ie nombolo 082 778 73 78 okanye Umongameli Wophando, u 
Professor Ashraf Kagee, ngokutsalela Ie nombolo (021) 808 3442. 
ISIPHELO 
Ngokusayina apha ngezantsi ubonisa ukuba uyifundile kwaye wayiqonda ifomu yemvumelwano kwaye 
uyav'Uma ukuthatha inxaxheba kule nkqubo yophando. 
Usayino lomthathi nxaxheba Umhla 
U sayino lomphandi Umhla 
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APPENDIXB 
1. Please indicate your gender here by placing a cross eX) in the appropriate box below! Nceda 
bonakalisa isini sakho ngokufaka unongxabalaza eX) kwibhokisi efanelekileyo apha ngezantsi: 
Male/ 
Ndoda 
Female / I 
Mfazi/Bhinqa ! 
I 
2. Please write your age here I Nceda bhala iminyaka yakho apha: 
3. What grade are you cunently in? I Ukweliphi ibanga ngoku? 
--------
81 
4. Please indicate which population group you belong to by placing a cross eX) in the appropliate box 
below I Nceda bonakalisa ukuba ungummi weliphi na iqela ngokufaka unongxabalaza eX) kwibhokisi 
efanelekileyo apha ngezantsi: 
Black I Mnyama 
Coloured / Webala 
White I J'vIhlophe 
Indian! Ndiya 
Asian / M-Asiya 
Other / Ezinye 
I 
5. Please note the example below / Nceda qaphela 10 rnzekelo ongezantsi: 
Very Low Risk I 
Ndisengciphekweni encinci kakhulu 
Very High Risk! 
Ndisengciphekvveni enktllu kakhulu 
____________________________ X ________________________ _ 
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Following the example above, please indicate with a cross eX) on the line below how much at risk you 
THINK you are of contracting HIV / Ulandela 10 mzekelo ongentla, nceda bonakalisa ngonongxabalaza (X) 
kulo mgca ongezantsi ubungakanani bengcipheko OCINGA ungakuyo yokusuleleka yiHIV 
Very Low Risk I 
Ndisengciphekweni encinci kakhulu 
Very High Risk I 
Ndisengciphekweni enkulu kak.~ulu 
6. Please note the example below / Nceda qaphela 10 mzekelo ongezantsi: 
Very Unwilling 
N dinomdla kakhulu 
Very Willing 
Andinamdla kakhulu 
x ------------------------------~ ~------------------------
Following the example above, please indicate how willing you are to participate in an HIV vaccine trial by 
placing a cross (X) on the line below / Ulandela 10 mzekelo ongentla, nceda bonakalisa ukuba unomdla 
kangakanani na ekuthatheni inxaxheba kuvavanyo/ukulingwa kweyeza elikhusela ukungosulelwa yiHIV 
ngokufaka unongxabalaza (X) kulo mgca ongezantsi: 
Very Willing 
Ndinomdla kakhulu 
Very Unwilling 
Andinamdla kakhulu 
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APPENDIXC 
fl. A placebo is a fake treatment that is similar to the real vaccine or drug! 
i Iplacebo liyeza elingelilo elifana neyeza lokukhusela okanye iyeza 
, 
I eliyobisayo/isiyobisi. 
2. In a clinical trial there are usually two groups of people: one group that 
receives the real vaccine or drug and the other group that receives a fake 
vaccine or drug (placebo) / Kuvavanyo iwasekliniki kudla ngokuba 
namaqela amabini abantu: Elinye iqela lifumana iyeza elililo lOkukhusela 
okanye isiyobisi ze abanye bafumane iyeza elingelilo lokukhuselalisiyobisi. I 
3. It is important that the individuals placed in each group in a clinical trial I 
are similar to each other in as many ways as possible / Kubalulekile ukuba I 
abantu ababekwe kwiqela ngalinye kuvavanyo lwasekliniki bafane 
kangangoko. 
4. In a clinical trial, neither the clinicians nor the participants know which 
I group has received the real vaccine or drug and which group has received 
I I the fake medication (placebo) / Kuvavanyo lwasekliniki, akunakubakho 
I I gqirha kwaye kungenakubakho bathathi-nxaxheba abanganolwazi ngokuba 
i 
leliphi iqela elifumene iyeza elililo okanye isiyobisi kunye nelo elifumene 
iyeza elingelilo(into efana neyeza kodwa elingelilo esetyenziswa 
ekuk..holiseni nje) 
5. Sometimes some participants in a clinical trial may recover from an 
illness even though they only receive the fake vaccine or drug (placebo) / 
I Ngamanye amaxesha abanye babathathi-nxaxheba kuvavanyo lwasekliniki I 
bangaziva bengasaguli/bephilile noxa befumene iyeza elingelilo okanye 
isiyobisi (into efana neyeza kodwa elingelilo esetyenziswa ekukholiseni 
I nje). 
6. vVhen testing a new medication or vaccine it is necessary to have a group 
that receives only a placebo. This will help researchers to determine 
whether the new medication works better than the fake medication 
83 
TRUE FALSE 
E\VE HAYI 
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(placebo) / Xa kuvavanyalkulingwa iyeza elitsha kumele kubekho iqela 
elifumana into efana neyeza kodwa elingelilo elisetyenziswa ek'l.lkholiseni 
I qha. Le nto inceda abaphandi ukuba baqinisekise ukuba ingaba eli yeza 
I 
elitsha lisebenza ngcono na kuneyezelingelilo (into efana neyeza kodwa 
elingelilo esetyenziswa ekukholiseni nje). 
7. HIV vaccines are given to help prevent someone from becoming infected 
with HIV / Amayeza akhusela ukungosulelwa yiHIV anikelwa ukunceda 
I umntu angosuleleki yiHIV. 
I 
8. HIV vaccines are given only to children, never to adults / Alllayeza i I 
akhusela ukungosulelwa yiHIV anikwa abantwana bodwa, hayi abantu I 
abadala. 
9. If a person receives a new HIV vaccine that does not work properly, he 
or she may not be protected from becoming infected with HIV / Amayeza I I I 
I 
amatsha akhusela ukungosulelwa yiHIV kumele avavanywe ukuze I I 
kwazeke/kubonakale ukuba ngokwenene ayasebenza ekukhuseleni umntu 
angosuleleki yiHIV. 
10. An HIV vaccine can never give you HIV or AIDS / Iyeza elikhusela 
ukungosulelwa yiHIV alingeke likunike iHIV okanye iAIDS. I 
! 11. HIV vaccines are tested on human beings only once they have been I I 
I I 
shown to be safe in animals I Amayeza akhusela ukungosulelwa yiHIV I 
avavanywa ebantwini kuphela xa sele kufunyaniswe ukuba akhuselekile 
kwizilwan yana. 
12. If you decide to participate in an HIV vaccine trial, you will receive 
infonllation about the trial before you are included in the study I Xa wenze 
isigqibo sokuthatha inxaxheba kuvavanyo/ukulingwa kwamayeza akhusela 
ukungosulelwa yiHIV, uzakufumana/uzakunikwa ulwazi malunga 
novavanyo phambi kOKllba ufakwe kule nkqubo yophando. 
13. People who want to enroll in an HIV vaccine trial will be asked to sign 
a fonn saying that they agree to participate before they are included in the 
I 
trial / Abantu abafuna ukubhalisela olu vavanyo/ukulingwa kweyeza 
elikhusela umntu angosulelwa yiHIV bazakucelwa ukuba basayine ifomu 
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exela ukuba bayavuma ukuthatha inxaxheba phambi kokuba bafakwe kolu 
vavanyo. 
14. If you receive an HIV vaccine it is possible that you may test HIV 
positive even though you are not really infected with HIV / Xa unikwe eli 
iyeza elikhusela ukungosulelwa yiHIV kusenokwenzeke ukuba 
ufunyaniswe uneHIV nangona ungosulelekanga kwaphela yiHIV. 
15. Ifpeople have unsafe sex, the HIV vaccine being tested might not 
protect them from becoming infected with HIV / Xa abantu besababelana 
ngesondo ngendlela engakhuselekanga, eli yeza elikhusela ukungosulelwa 
yiHIV elivavanywa kubo lingangabakhuseli ekosulelekeni yiHIV. 
16. People who take part in HIV vaccine trials will receive free health care 
at the study clinic only for trial-related medical problems / Abantu 
abathatha inxaxheba kuvavanyo/ukulingwa kweyeza elikhusela 
ukungosulelwa yiHIV bazakongiwa simahla/ngaphandle kwentlawulo 
kwikliniki eyodwa eqhuba olu phando malunga nokugula okunokubakho 
okudibene nolu vavanyo. 
17. If you enroll in an HIV vaccine trial you will get the appropriate 
medication, medical tests, and HIV tests regularly all the way through the 
trial I Xa ubhalisile kolu vavanyo/ukulingwa kwamayeza akhusela 
ukungosulelwa yiHN uza kufumana unyangongamayeza olufane1ekileyo, 
ukuxilongwa, novavanyo IweHIV rhoqo lude lugqitywe olu vavanyo. 
18. If you enroll in an HIV vaccine trial, each time you visit the trial site 
you will be asked questions about your health and sexual behaviour / Xa 
ubhalisile kolu vavanyo/ukulingwa kwamayeza akhusela ukungosulelwa 
yiHIV, ngalo lonke ixesha usiya kule ndawo yovavanyo uza kubuzwa I I 
imibuzo emalunga nempilo yakho kunye nendlela oziphethe ngayo 
ngokwezesondo. 
19. People who take part in an HIV vaccine trial will be allowed to stop 
their involvement in the trial at any time / Abantu abathatha inxaxheba kolu 
vavanyo lwamayeza akhusela ukungosulelwa yiHIV bazakuvunyelwa I 
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I ukuba bayeke uk'Uthatha inxaxheba nanini na. 
I j I 
20. An HIV vaccine trial is a study in which an HIV vaccine is tested to see I 
if it prevents people from contracting HIV I Uvavanyo/ukulingwa kweyeza I 
elikhusela ukungosulelwa yiHIV yinkqubo yophando apho iyeza elikhusela 
umntu angosulelwa yiHIV livavanywa ukuze kufunyaniswe uba ingaba 
liyabakhusela na abantu ekosulelekeni yiHIV. 
21. In an HIV vaccine trial, scientists want to know whether there are fewer 
HIV infections in the group that receives the HIV vaccine than in the group I 
that receives the fake HIV vaccine (placebo) I Kuvavanyo/ukulingwa 
kweyeza elikhusela ukungosulelwa yiHIV, iinzululwazi zifuna ukuqonda 
ukuba ingaba ukosuleleka kukambalwa (kukancinci) na bviqela elifumene 
iyeza elililo lokukhusela ukungosulelwa yiHIV kuneqela elifumene iyeza 
elingelilo elikhusela ukungosulelwa yiHIV (into efana neyeza kodwa 
elingelilo esetyenziswa ukukholiseni). 
22. If fewer people in the group that receives the real vaccine develop HIV 
than those who are given the fake HIV vaccine (placebo), we can say that 
the vaccine is working effectively I Xa bembalwa abantu ababonakala 
beneHIV kwiqela elifumene iyeza elililo kunabo abakwiqela ebelinikwe 
iyeza elingelilo (into efana neyeza kodwa elingelilo esetyenziswa 
ukukholiseni), sinokuthi eli yeza lisebenza ngokufanelekileyo. 
23. In an HIV vaccine trial, all participants have an equal chance of being 
placed in the group that receives the real vaccine or the group that receives 
the fake vaccine (placebo) / Kuvavanyo/ukulingwa kweyeza elikhusela 
ukungosulelwa yiHIV, bonke abathatha inxaxheba banethuba elilinganayo 
lokufakwalkungeniswa kwiqela elifumana iyeza elililo okanye iqela 
elifumana iyeza elingelilo (into efana neyeza kodwa elingelilo 
I esetyenziswa ekukholiseni). 
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APPENDIXD 
Strongly Disagree! I Agree! Strongly 
Disagree! Andivnmelani I Ndiyavnmelana Agree I 
Andiyavnmelani N diyavnmelana 
kakhulu kakhnln 
124. People with AIDS are 
I dirty I Abantu abaneAIDS I I 
I bamdaka. 
I 25. People who have AIDS I 
are cursed I Abantu 
abaneAIDS baqalekisiwe. 
26. People who have AIDS 
should be ashamed I Abantu i 
abaneAIDS kumele babe I I 
neentloni. 
27. It is safe for people who 
I have AIDS to work with I 
children / Kukhuselekile I , 
ukuba abantu abaneAIDS 
basebenze nabantwana. I 
28. People with AIDS must 
expect some restrictions on 
their freedom I Abantu I I I 
abaneAIDS kumele 
bayilindele imiqathango 
ethile malunga 
nokuzimelalukuziphatha 
kwabo. I 
I 
29. A person with AIDS 
must have dome something ! 
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I wrong and deserves to be I , I ! I I punished / Umntu oneAIDS 
I udla ngoba enze I I 
! 
okungalunganga kwaye I 
kumele ohlwaywe. I 
30. People who have HIV 
! 
should not be isolated / 
I Abantu abaneAIDS kumele 
I I bangangabi bodwa. 
i 
31. I do not want to be 
friends with someone who 
I 
has AIDS / Andifuni kwenza I 
ubuhlobo nomntu oneAIDS. 
32. People who have AIDS 
should be allowed to work / 
I Abantu abaneAIDS kumele 
I 
bavunyelwe ukuba 
I basebenze. 
i 
i 
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APPENDIXE 
Never Sometimes Often I Routinely I 
Zange /Ngamauye Kaninzi Ngokuqhelekileyo 
amaxesha 
33. I feel content and at peace with myself / i 
Ndiziva ndikholisekile kwaye ndinoxolo I 
I ngmnlngesiqu sam. 
34. I find each day interesting and challenging 
/ Ndifumanisa usuku ngalunye lunomtsalane 
kwaye lucela umngeni. 
35. I believe that my life has purpose I I 
Ndinenkolelo yokuba ubomi bam bunenjongo. 
36. I like myself / Ndiyazithanda. 
37. I ask for infoffilation from health 
professionals about how to take good care of 
myself / Ndicela ulwazi kumagosa empilo 
I I I ngendlela elungileyo yokuzikhathalela. 
38. I discuss my health concerns with health 
professionals / Ndixoxa iingxakiliinkxalabo 
ngempilo yam namalungu ezempilo. 
39. I check my blood pressure / Ndiyalwenza 
uvavanyo loxinzelelo lwegazi. I I 
40. I exercise vigorously for 20 minutes or 
more at least three times a week (such as brisk 
walking, bicycling, aerobic dancing etc.) I 
Ndizilolonga ngamandla kangangemizuzu eyi 
20 okanye nangaphezulu ubuncinane kathathu 
ngeveki (ngolu hlobo ukuhamba 
ngokukhawuleza, ukuqhuba ibhayisikile, 
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ngomdaniso wokuzilolonga njalo njalo.) I I 
41. I do stretching exercises at least three 
I 
I 
times per week / Ndizilolonga ngokutwabuiula I 
imisipha ubuncinci kathathu ngeveki. I 
42. I eat three meals daily / Nditya kathathu 
ngemml. 
43. I eat breakfast i Ndiyasitya isidlo sakusasa. I I I I 
44. I touch and am touched by people I care I I I 
about I Ndiyabachukumisa kwaye nam , I 
ndiyachukumiseka ngabantu 
endibakhathalelayo. 
45. I maintain meaningful and fulfilling 
relationships with others / Ndiyabugcina 
ubudlelwane obunentsingiselo nobufezekileyo 
nabanye. 
46. I relax my muscles before I sleep I 
Ndiyekelela imisipha yam phambi kokuba 
ndilale. 
47. I use specific methods to control my stress 
/ Ndisebenzisa indlela ethile ukula\Vula 
isigxiniso esimandla. 
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APPENDIXF 
Participating in an HIV vaccine trial will be I Ukuthatha inxaxheba 
kuvavanyo/ukulingwa kweyeza elikhusela ukungosulelwa yiHIV kuza kuba: 
54. Hannfull Nengozi 
2 3 4 5 6 I 7 1 i 
55. Good / 
l 
I 
Kokulungileyo 1 2 3 4 5 6 1 7 I 
I 
I 
56. Pleasant I Mnandi 
1 2 3 4 5 6 7 
57. ~Worthless I 
1 2 3 4 5 6 7 
Kolnmgento 
58. Important I 
1 2 3 4 5 6 7 
Kubaluleka 
59. Admirable / 
1 2 3 4 5 6 7 
Kokuncomekayo 
160. Nccessary / 
1 2 3 I 4 5 6 7 Kokufunekayo I I 
61. Beneficial i 
1 2 3 4 5 6 7 
Noncedo I I I 
62. Silly / Bubuhiba 
1 2 3 4 5 6 7 
I 
91 
I Beneficial I Luncedo 
I Bad / Kokubi 
I 
I 
I 
I 
Unpleasant I 
Kungemnandi 
Worthwhile I 
I 
Lulutho I 
Unimportant / ! 
Kok'Ungabalulekanga 
Non Admirable I 
Ko]mngancomeki yo 
Unnecessary / 
Kokungafunekiyo 
Non beneficial! 
Kokungenancedo 
Clever / Bubulumko 
Stellenbosch University  http://scholar.sun.ac.za
92 
APPENDIXG 
Strongly Disagree/ I Agree/ Strongly 
Disagree/ Andivumelani I Ndiyavumelana Agree/ 
i Andivumeiani , N diyavumelana 
I I kakhulu kakhulu 
48. Most people who are 
important to me think that I 
should participate in an HIV 
vaccine trial / Abantu 
abaninzi ababalulekileyo kum 
bacinga ukuba kumele 
ndithathe inxaxheba 
kuvavanyo/ukulingwa I I 
I 
kweyeza elikhusela 
ukungosulelwa yiHIV. 
49. It is expected of me to 
participate in an HIV vaccine I 
trial! Kulindeleke ukuba 
ndithathe inxaxheba 
I kuvavanyo/ukulingwa I 
kweyeza elikhusela I I 
ukungosulelwa yiHIV. I 
50. I feel under social 
pressure to participate in an 
HIV vaccine trial! . Ndiziva 
I 
ndiphantsi 
kwesinyanzelo/koxinzelelo ! 
lwabanye ukuba ndithathe 
inxaxheba 
kuvavanyo!ukulingwa 
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I kweyeza elikhusela 
i ukungosulelwa yiHN. 
! 
51, Most people who are 
important to me are willing to 
pmiicipate in an HIV vaccine 
trial / Abantu abaninzi 
ababalulekileyo kum 
bayafuna ukuthatha 
inxaxheba kuvavanyol 
ukulingwa kweyeza 
elikhusela ukungosulelwa 
yiHIV, 
52, Doing what significant 
people in my life think I shoulc 
do is important to me I 
Ukwenza oko abantu 
ababalulekileyo ebomini barn 
abacinga ukuba kumele 
ndikwenze kubalulekile kum. 
53. Approval of my 
participation in an HIV 
vaccine trial is important to 
me ! Ukwamkeleka kwam 
kolu vavanyol ukulingwa 
kweyeza elikhusela 
ukungosulelwa yiHIV 
kubalulekile kum. 
93 
I 
I 
I 
; 
I I I I I I ! 
I 
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APPENDIXH 
I Strongly I Disagree I Agree I ! Strongly 
Disagree I Andivumelani Ndiyavumelana Agree I 
Andivumelani Ndiyavumelana 
kakhulu kakhulu 
63. I am confident that I 
could participate in an HIV I I 
vaccine trial if I wanted to / 
Ndikholelwa ekubeni 
ndingayithatha inxaxheba I 
I kuvavanyo/ukulingwa 
I 
kweyeza elikhusela I I 
ukungosulelwa yiHIV. I I 
64. It would be very difficult 
for me to participate in an 
HIV vaccine trial! 
Kunganzima kakhulu kum 
ukuthatha inxaxheba 
kuvavan yo!ukulingwa 
I kweyeza elikhusela 
ukungosulelwa yiHIV. 
I 
65. The decision to 
pat1icipate in an HIV vaccine 
I trial is beyond my control / 
I -I I Isigqibo sokuthatha 
inxaxheba i i I I 
kuvavanyo/ukulingwa I I 
I kweyeza elikhusela I i 
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ukungosulelwa yiHIV 
singaphaya kwamandla am 
66. Whether or not I decide 
to participate in an HIV 
vaccine trial is entirely up to 
me I Nokuba ndithatha 
inxaxheba okanye 
andiyithathi kuvavanyol 
ukulingwa kweyeza 
elikhusela ukungosulelwa 
yiHIV oko kuxhomekeke 
kum ngokupheleleyo. 
67. I would not be able to I 1 
participate in an HIV vaccine 
I 
I 
I 
trial even if I wanted to I I 
Andinav/ukwazi ukuthatha ! 
inxaxheba kuvavanyo/ 
ukulingwa kweyeza 
elikhusela ukungosulelwa 
yiHIV nokuba bendifuna. I 
I 
68. I could easily participate 
I i in an HIV vaccine trial if I I 
wanted to I Kungalula 
ukuthatha inxaxheba 
i 
kuvavanyol ukulingwa 
kweyeza elikhusela 
ukungosulelwa yiHIV xa 
ndifuna. 
i 69. It is up to me to decide I I 
I 
I I 
I l whether or not I will I , j 
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participate in an HIV vaccine I I 
I trial / Kuxhomekeke kum I I I ukwenza isigqibo sokuba I I I 
I ndingakwazi okanye I 
ndingangabvazi ukuthatha 
inxaxheba kuvavanyol 
I 
ukulingwa kweyeza 
I elikhusela ukungosulelwa 
yiHIV. I 
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